var title_f7_41_7824="Hives PI";
var content_f7_41_7824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hives",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hives are raised, red patches of skin that are usually very itchy. They usually come and go within a few hours. But they can show up again and again in some people.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Samel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7824=[""].join("\n");
var outline_f7_41_7824=null;
var title_f7_41_7825="Atroph rhin exp nasal cavity";
var content_f7_41_7825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiographic findings of primary atrophic rhinitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note expansion of nasal cavity (particularly on the left side), resorption of inferior turbinate bones, bowing of lateral nasal wall, and atrophy of nasal and turbinate mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chand, MS, MacArthur, CJ. Primary atrophic rhinitis: a summary of four cases and review of the literature. Otolaryngol Head Neck Surg 1997; 116:554. Copyright &copy; 1997 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7825=[""].join("\n");
var outline_f7_41_7825=null;
var title_f7_41_7826="Patient information: Transsexualism (The Basics)";
var content_f7_41_7826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86378\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/160\">",
"         Adult female external genitalia",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"          Male reproductive anatomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/1/30738\">",
"         Patient information: Normal sexual development (puberty) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Transsexualism (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H91639106\">",
"      <span class=\"h1\">",
"       What is transsexualism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Transsexualism is a condition that causes a person to feel that they were born as the wrong sex. A male transsexual has a strong desire to look like and to live life as a female. A female transsexual has a strong desire to look like and to live life as a male. Transsexuals might take medicines or have surgery to change their bodies so they can look and feel more like the opposite sex.",
"     </p>",
"     <p>",
"      Transsexualism is not the same as homosexuality, which means a person is sexually attracted to people of the same sex. A transsexual person is also different than a &ldquo;transgender&rdquo; person. Transgender people want to live as the opposite sex at least part of the time, but do not want surgery to change their bodies. Transsexuals also differ from &ldquo;transvestites&rdquo; (also called &ldquo;cross-dressers&rdquo;), who sometimes dress like a member of the opposite sex.",
"     </p>",
"     <p>",
"      Transsexualism is also called &ldquo;gender identify disorder.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91639121\">",
"      <span class=\"h1\">",
"       What are the symptoms of transsexualism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom of transsexualism is feeling that you were born the wrong sex. Many adult transsexuals say they had these feelings as children, before they went through &ldquo;puberty.&rdquo; Puberty is the term for the changes the body goes through during the pre-teen and teen years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91639136\">",
"      <span class=\"h1\">",
"       When and how is transsexualism treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Experts say that children with gender identity issues should not be treated until they are at least 16 years old. For some children, doctors prescribe medicines that stop puberty. This prevents sexual changes in children&rsquo;s bodies and gives them more time to figure out if they are transsexual. Most children and young teens who have gender identity issues do NOT become transsexuals. If they are transsexual, they can start medical treatment around age 16, but should wait to have surgery until they turn 18.",
"     </p>",
"     <p>",
"      Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Therapy with a counselor (such as a psychiatrist, psychologist, nurse, or social worker) - Talking with a counselor about your condition can help you better understand what to expect from the surgery and medicines. He or she might also put you in touch with other transsexuals who have already changed to their new sex. This can help you get a better idea of what you might experience as your body changes, and what problems or challenges you might face.",
"        <br/>",
"        <br/>",
"        Part of the therapy includes a &ldquo;real life test,&rdquo; which should be done either before or soon after you start medical treatment. A real life test means that you live as a person of the opposite sex for at least 1 year. Experts advise that you do this to experience what your life will be like in your new role, before you have surgery.",
"       </li>",
"       <li>",
"        Medicines &ndash; These include sex hormones and medicines that block sex hormones. Hormones are chemical messengers that turn on and off different process in the body. Sex hormones cause changes in the sexual organs and other parts of the body. These medicines are taken as pills, injections (shots), or a gel that you rub on your skin.",
"        <br/>",
"        <br/>",
"        Male-to-female transsexuals take medicines that block male hormones (called &ldquo;androgens&rdquo;). Androgens cause hair to grow on the body and face, so medicines that block androgens help lessen body hair. They then take female hormones (&ldquo;estrogens&rdquo;) that make their breasts grow.",
"        <br/>",
"        <br/>",
"        Female-to-male transsexuals take androgens. This usually stops their monthly periods. Androgens also cause women to grow hair on their faces. It also makes the &ldquo;clitoris&rdquo; grow (",
"        <a class=\"graphic graphic_figure graphicRef53704 \" href=\"UTD.htm?0/10/160\">",
"         figure 1",
"        </a>",
"        ). The clitoris is the bundles of nerves above the vagina that gives women sexual pleasure.",
"       </li>",
"       <li>",
"        Surgery &ndash; The surgery for male-to-female transsexuals includes a creating a pouch that serves as a vagina. The surgeon uses the skin of the penis to line the inside of the new vagina. He or she uses the skin of the scrotum (",
"        <a class=\"graphic graphic_figure graphicRef68075 \" href=\"UTD.htm?21/43/22194\">",
"         figure 2",
"        </a>",
"        ) to create the folds of tissue around the vagina (called &ldquo;labia.&rdquo;) Some people also have surgery to make their breasts larger.",
"        <br/>",
"        <br/>",
"        The surgery for female-to-male transsexuals includes removing the breasts, uterus, and ovaries. Some people also have surgery to create a penis. The surgeon uses tissue from the person&rsquo;s arm or leg to create a penis. He or she can also lengthen the tube that carries urine from the bladder to outside the body (called the &ldquo;urethra&rdquo;). That way, the person can urinate standing up. The labia can be used to create a scrotum. Small plastic balls can be put inside the scrotum to make testicles.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91639151\">",
"      <span class=\"h1\">",
"       Can treatments for transsexualism cause any medical problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The hormones that transsexuals take might make them slightly more likely to have certain medical conditions, including dangerous blood clots, heart disease, breast cancer, and prostate cancer. Experts say that transsexuals who take hormones should see their doctors every 3 months for the first year of treatment, then 1 or 2 times a year after that. The doctor should test the person&rsquo;s hormone level and check for any medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91639168\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"       Patient information: Normal sexual development (puberty) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/41/7826?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86378 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7826=[""].join("\n");
var outline_f7_41_7826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91639106\">",
"      What is transsexualism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91639121\">",
"      What are the symptoms of transsexualism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91639136\">",
"      When and how is transsexualism treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91639151\">",
"      Can treatments for transsexualism cause any medical problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91639168\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86378\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/160\">",
"      Adult female external genitalia",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22194\">",
"       Male reproductive anatomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_41_7827="Oxiconazole: Drug information";
var content_f7_41_7827=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxiconazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/16/35075?source=see_link\">",
"    see \"Oxiconazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxistat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Oxistat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea corporis/tinea cruris:",
"     </b>",
"     Topical: Cream, lotion: Apply to affected areas 1-2 times daily for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea pedis:",
"     </b>",
"     Topical: Cream, lotion: Apply to affected areas 1-2 times daily for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea versicolor:",
"     </b>",
"     Topical: Cream: Apply to affected areas once daily for 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F204554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Tinea corporis, tinea cruris, tinea pedis, tinea versicolor:",
"     </b>",
"     Children &ge;12 years and Adolescents:  Topical: Cream, lotion: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxistat&reg;: 1% (30 g, 60 g [DSC], 90 g) [contains benzoic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxistat&reg;: 1% (30 mL [DSC], 60 mL) [contains benzoic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15244623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Avoid occlusive dressings. Wash hands before and after use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea (pityriasis) versicolor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Burning (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic contact dermatitis, dyshidrotic eczema, erythema, fissure, folliculitis, irritation, maceration, nodules, pain, papules, rash, scaling, stinging, tingling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxiconazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; not for ophthalmologic, oral, or vaginal use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, teratogenic effects were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F204535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic absorption is low, however, the manufacturer reports that oxiconazole is excreted in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Oxistat External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (60 g): $326.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Oxistat External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 mL): $174.80",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F204536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antimycolin (TW);",
"     </li>",
"     <li>",
"      Derimine (JP);",
"     </li>",
"     <li>",
"      Liderman (AT);",
"     </li>",
"     <li>",
"      Myfungar (CZ, DE, MX, RU);",
"     </li>",
"     <li>",
"      Oceral (CH, TR);",
"     </li>",
"     <li>",
"      Oceral GB (NZ);",
"     </li>",
"     <li>",
"      Okinazole (JP);",
"     </li>",
"     <li>",
"      Oxicone (TW);",
"     </li>",
"     <li>",
"      Oxistat (AR, MX);",
"     </li>",
"     <li>",
"      Oxitrat (BR);",
"     </li>",
"     <li>",
"      Oxizole (TW);",
"     </li>",
"     <li>",
"      Salongo (ES);",
"     </li>",
"     <li>",
"      Zoderm (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The cytoplasmic membrane integrity of fungi is destroyed by oxiconazole which exerts a fungicidal activity through inhibition of ergosterol synthesis. Effective for treatment of tinea pedis, tinea cruris, tinea corporis, and tinea versicolor. Active against",
"     <i>",
"      Trichophyton rubrum",
"     </i>",
"     ,",
"     <i>",
"      Trichophyton mentagrophytes",
"     </i>",
"     ,",
"     <i>",
"      Trichophyton violaceum",
"     </i>",
"     ,",
"     <i>",
"      Microsporum canis",
"     </i>",
"     ,",
"     <i>",
"      Microsporum audouinii",
"     </i>",
"     ,",
"     <i>",
"      Microsporum gypseum",
"     </i>",
"     ,",
"     <i>",
"      Epidermophyton floccosum",
"     </i>",
"     ,",
"     <i>",
"      Candida albicans",
"     </i>",
"     , and",
"     <i>",
"      Malassezia furfur",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: In each layer of the dermis; very little systemically after one topical dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To each layer of the dermis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;0.3%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9727 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7827=[""].join("\n");
var outline_f7_41_7827=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204543\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204562\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204545\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204554\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204546\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204528\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204516\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15244623\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204529\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204560\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204532\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204520\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299802\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222051\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204525\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204534\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204547\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204535\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570483\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204536\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204519\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204531\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9727\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9727|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/16/35075?source=related_link\">",
"      Oxiconazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_41_7828="Nedocromil: Patient drug information";
var content_f7_41_7828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nedocromil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     see \"Nedocromil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/37/23122?source=see_link\">",
"     see \"Nedocromil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alocril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alocril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nedocromil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep taking this drug to stop the allergy. Once signs start, this drug will not help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11508 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7828=[""].join("\n");
var outline_f7_41_7828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200225\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200226\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017383\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017382\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017387\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017388\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017390\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017385\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017386\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017391\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017392\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=related_link\">",
"      Nedocromil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/37/23122?source=related_link\">",
"      Nedocromil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_41_7829="TR four chamber color Doppler echo";
var content_f7_41_7829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/56009/4chcodtr_conv.mp4?title=TR+four+chamber+color+Doppler+echo\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation in carcinoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from 2-D echocardiogram with color flow Doppler shows severe tricuspid regurgitation. The patient had a carcinoid syndrome with fibrotic tricuspid valve leaflets that were stenotic and immobile, remaining opened during systole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7829=[""].join("\n");
var outline_f7_41_7829=null;
var title_f7_41_7830="Autoimmune hepatitis Low";
var content_f7_41_7830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune hepatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver biopsy in autoimmune hepatitis showing portal and periportal mononuclear cell infiltration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Edward L Krawitt, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7830=[""].join("\n");
var outline_f7_41_7830=null;
var title_f7_41_7831="Optical coherence tomography in the gastrointestinal tract";
var content_f7_41_7831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Optical coherence tomography in the gastrointestinal tract",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/41/7831/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/41/7831/contributors\">",
"     Shai Friedland, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/41/7831/contributors\">",
"     Jacques Van Dam, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/41/7831/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/41/7831/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/41/7831/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/41/7831/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/41/7831/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components borrowed from the telecommunications industry have been applied to medical imaging to improve resolution as never before. Optical coherence tomography (OCT) is an emerging medical imaging technology that relies on the backscattering of light to obtain cross-sectional images of tissue. Many of the early applications of OCT were in ophthalmology, where the transparency of anterior structures of the eye facilitated high-resolution imaging of the retina. More recently, there have been several pilot studies using OCT in the gastrointestinal tract. These have demonstrated the feasibility of this technology to enhance endoscopic imaging of the superficial layers of the esophagus, stomach, bile ducts, pancreatic duct, and colon. OCT imaging has demonstrated anatomic structures such as crypts and glands that could potentially permit endoscopists to diagnose mucosal abnormalities such as Barrett's esophagus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCT is similar in principle to ultrasonography but uses light waves rather than acoustical waves. As in B-mode ultrasonography, a quantitative measurement of backscattering is performed at each axial depth, and the measurements are repeated at different transverse positions. In this manner, a linear or radial two-dimensional map of backscattering strength is acquired [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of optical backscattering is performed by low coherence interferometry [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/4\">",
"     4",
"    </a>",
"    ]. This method uses a low coherence light source such as a superluminescent diode, which typically has a coherence length of approximately 20 micrometers. The incident light is split in two by an optical beam splitter, with one beam directed to the tissue via an optical fiber and the other beam directed to a mirror located at a precisely controlled distance. The backscattered light from the tissue is combined with the reflected light from the mirror. This results in interference only when the path lengths match to within the 20 microns of the coherence length of the light source. A quantitative measurement of optical backscattering at different depths is obtained by measuring the degree of interference at each mirror position as the mirror is moved.",
"   </p>",
"   <p>",
"    The coherence length of the light source determines the maximal axial resolution that can be obtained. Transverse resolution is determined by the spot size of the focused beam directed at the tissue and the amount that the apparatus is translated at each during the scan; it is typically also approximately 20 microns. OCT is typically performed with near infrared light because tissue is relatively transparent; longer wavelengths penetrate deeper into biological tissues at these frequencies. Scattering of light in tissue limits the depth of scanning to approximately 1 to 2 mm in the gastrointestinal tract, generally restricting OCT imaging to the mucosa and submucosa when performed during endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNICAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCT is typically performed using catheters passed through the accessory channel of standard gastroscopes, colonoscopes, or duodenoscopes (",
"    <a class=\"graphic graphic_picture graphicRef50024 \" href=\"UTD.htm?5/59/6064\">",
"     picture 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radial and linear scanning catheter probes create radial and linear images, respectively",
"     </li>",
"     <li>",
"      Linear catheter probes have generally yielded better quality images",
"     </li>",
"     <li>",
"      A water interface, such as is required for ultrasound imaging, is not required",
"     </li>",
"     <li>",
"      Tissue contact is not required",
"     </li>",
"     <li>",
"      Resolution is within the range of approximately 7 to 20 micrometers",
"     </li>",
"     <li>",
"      Scanning depth is limited to 1 to 2 mm",
"     </li>",
"     <li>",
"      Scanning at four frames per second provides real time imaging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with endoscopic ultrasound systems, both radial scanning and linear scanning catheters have been described. Most studies done to date have used linear probes, which generally yield superior quality images. Unlike endoscopic ultrasound, OCT can be performed through air so tissue contact or coupling is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/5\">",
"     5",
"    </a>",
"    ]. Scanning depth is limited to 1 to 2 mm because of scattering of light by tissue. Most of the systems described achieve a resolution of approximately 7 to 20 micrometers, which is sufficient for visualizing mucosal glands, crypts, and villi, but not cellular features such as nuclear dysplasia. In contrast, high frequency ultrasound (20 MHz) resolution is typically 100 to 200 micrometers, which is insufficient to visualize many of the multicellular features seen with OCT. In newer OCT systems, a 512 by 512 pixel image can be acquired in one-quarter of a second; older systems required several seconds to scan an image, which sometimes lead to blurring from patient motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TECHNICAL ADVANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research in OCT is continuing on several fronts. Reports of substantially higher resolution OCT systems relying on femtosecond laser pulses support the potential for additional improvements in imaging capabilities of gastrointestinal epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/6\">",
"     6",
"    </a>",
"    ]. A catheter-based femtosecond laser system that can be used during endoscopy has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of color Doppler to OCT has been used to identify subsurface blood vessels in experimental and clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. One group used a color Doppler OCT device in an in vivo rat model and concluded that the device could be useful clinically in monitoring hemostatic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second group used Doppler OCT to study a variety of conditions in the gastrointestinal tract including cancer, esophageal varices, and gastric antral vascular ectasia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/10\">",
"     10",
"    </a>",
"    ]. The combination of high-resolution imaging and Doppler provided striking images of the microcirculation in various disease states.",
"   </p>",
"   <p>",
"    Spectroscopic OCT imaging is an extension of ultra high resolution OCT. It uses the broad spectral bandwidth of the optical source to obtain information from the spectral content of the backscattered light. In vitro studies in Barrett's esophagus showed that spectral OCT improved the contrast of OCT images [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/11\">",
"     11",
"    </a>",
"    ]. It may also be possible to quantify localized tissue hemoglobin oxygenation by spectroscopic OCT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/12\">",
"     12",
"    </a>",
"    ]. These advancements in OCT imaging show promise for future clinical applications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     OCT of the esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have described features of normal and abnormal esophageal mucosa on OCT during endoscopy. In the normal esophagus, several distinct layers are clearly visualized: a relatively homogeneous epithelium, a high backscattering lamina propria, a low scattering muscularis mucosa, a high scattering submucosa, and a low scattering and thick muscularis propria (",
"    <a class=\"graphic graphic_picture graphicRef73005 \" href=\"UTD.htm?6/43/6834\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ]. By contrast, the uniformly layered structure is disrupted in Barrett's esophagus and multiple crypt and gland-like structures are seen as pockets of low backscattering (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56571 \" href=\"UTD.htm?34/50/35620\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. Several cases of esophageal adenocarcinoma have been described where large, low-scattering pockets (corresponding to mucin) and a disorganized appearance were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Finally, OCT has been used to stage esophageal squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Barrett's esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first prospective evaluation of OCT in the esophagus during endoscopy, three criteria were used to diagnose specialized intestinal metaplasia (Barrett's esophagus) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of normal esophageal or gastric morphology",
"     </li>",
"     <li>",
"      Inhomogeneous tissue contrast",
"     </li>",
"     <li>",
"      Presence of submucosal glands",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of at least two of the three criteria was found to be 97 percent sensitive and 92 percent specific using histopathology as the standard. However, it is difficult to directly compare these results to previous studies estimating the accuracy of visual identification of intestinal metaplasia on endoscopy because the OCT study set consisted mainly of normal esophagus, Barrett's esophagus, and normal stomach. In practice, the main difficulty in diagnosing intestinal metaplasia visually during endoscopy arises in distinguishing Barrett's from inflammation in the distal esophagus and cardia, and in distinguishing intestinal metaplasia from the less worrisome gastric metaplasia. All of the false positives in this study were in fact due to cardiac tissue with or without inflammation, and it is therefore likely that the specificity would have been substantially lower if the study would have included a more clinically representative set of samples.",
"   </p>",
"   <p>",
"    Several studies have evaluated the accuracy of OCT in detection of dysplasia in Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Because the resolution of standard OCT is insufficient to assess cellular features of dysplasia, an assessment of dysplasia and cancer is generally based upon larger scale features such as glandular organization and epithelial scattering intensity.",
"   </p>",
"   <p>",
"    In one study, 177 OCT images were reviewed by a blinded investigator and assessed for high-grade",
"    <span class=\"nowrap\">",
"     dysplasia/intramucosal",
"    </span>",
"    carcinoma by evaluating the degree of surface maturation and gland organization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/22\">",
"     22",
"    </a>",
"    ]. Sensitivity and specificity were 83 and 75 percent, respectively, when these features were combined to form a dysplasia index.",
"   </p>",
"   <p>",
"    A second group used OCT to assess Barrett's esophagus for the presence of any level of dysplasia (low- or high-grade or cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/23\">",
"     23",
"    </a>",
"    ]. The endoscopist performing the procedure evaluated the OCT images for dysplasia, relying on features such as focal areas of decreased light scattering and focal loss of mucosal structure and organization. Sensitivity and specificity were 68 and 82 percent, respectively. This group also described a computer-aided diagnosis algorithm for detection of dysplasia that had a sensitivity and specificity of 82 and 74 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, OCT has been used to detect buried Barrett's epithelium following radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=see_link&amp;anchor=H17#H17\">",
"     \"Radiofrequency ablation for Barrett's esophagus\", section on 'Buried Barrett's'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCT has been used in the preoperative staging of esophageal squamous cell carcinoma. In a study of 62 patients, OCT was used to categorize the depth of invasion into one of three categories: epithelium or lamina propria, muscularis mucosa, or submucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/20\">",
"     20",
"    </a>",
"    ]. The OCT image criteria were established using findings from the first 16 patients. The criteria were subsequently evaluated in the other 46 patients, comparing the results of OCT with the results of the histologic examination of the resected specimens. The accuracy of OCT for determining involvement of the",
"    <span class=\"nowrap\">",
"     epithelium/lamina",
"    </span>",
"    propria, muscularis mucosa, or submucosa was 95, 85, and 91 percent, respectively.",
"   </p>",
"   <p>",
"    A second study included 123 patients with 131 superficial esophageal squamous cell carcinomas. OCT accurately characterized 118 (90 percent) of the tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/27\">",
"     27",
"    </a>",
"    ]. Five tumors (4 percent) were overstaged, and eight tumors (6 percent) were understaged. Of the tumors that were limited to the",
"    <span class=\"nowrap\">",
"     epithelium/lamina",
"    </span>",
"    propria, OCT correctly staged 88 of 93 (95 percent), and of the tumors that involved the muscularis",
"    <span class=\"nowrap\">",
"     mucosa/submucosa,",
"    </span>",
"    OCT correctly staged 30 of 38 (79 percent). The accuracy of OCT in staging tumors limited to the",
"    <span class=\"nowrap\">",
"     epithelium/lamina",
"    </span>",
"    propria was higher than that of high-frequency probe-based endoscopic ultrasound (95 versus 81 percent, p&lt;0.01).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     OCT of the stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no large studies of OCT in the stomach. OCT images of the stomach are generally characterized by low tissue contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/17\">",
"     17",
"    </a>",
"    ]. It can be difficult to differentiate the superficial mucosal layers from the muscularis mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The relatively thick superficial glandular epithelium also causes poor visualization of the deeper layers, making it difficult to evaluate the muscularis propria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     OCT of the colon and small bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The full thickness of the colonic wall can often be seen on OCT: the superficial mucosa with visualization of crypts, the highly scattering submucosa, the weakly scattering muscularis propria, and the thin highly scattering serosal stripe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/13,28\">",
"     13,28",
"    </a>",
"    ]. Images of small bowel clearly demonstrate mucosal villi and can be used to identify villous atrophy in celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/29\">",
"     29",
"    </a>",
"    ]. Adenomas in the colon have been described with expanded glands in the superficial mucosa, mucosal cysts, and an uneven surface. Adenocarcinoma has also been described with complete loss of mucosal architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/18\">",
"     18",
"    </a>",
"    ]. In ulcerative colitis, superficial mucosal ulcers and other mucosal characteristics can be seen on OCT that correlate well with histologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study suggested that hyperplastic and adenomatous polyps had a distinct appearance on OCT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/32\">",
"     32",
"    </a>",
"    ]. Hyperplastic polyps generally had an organized crypt pattern and overall scattering intensity that was relatively similar to normal tissue, while adenomatous polyps demonstrated an absence of an organized crypt pattern and a decrease in overall scattering intensity.",
"   </p>",
"   <p>",
"    Another study of colectomy specimens found that OCT could help predict transmural inflammation, making it potentially useful for distinguishing Crohn's disease from other forms of colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/33\">",
"     33",
"    </a>",
"    ]. The authors subsequently used the ex-vivo criteria to evaluate 40 patients with known Crohn's disease and 30 patients with known ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/34\">",
"     34",
"    </a>",
"    ]. A disrupted layered structure was apparent in 36 patients with Crohn's disease (90 percent) compared with only 17 percent of patients with ulcerative colitis. Sensitivity and specificity of the disrupted layered structure for distinguishing Crohn's disease from ulcerative colitis were 90 and 83 percent, respectively. The authors concluded that OCT may be useful for distinguishing Crohn's disease from ulcerative colitis. Whether the test characteristics found in this study will hold true (especially when evaluating patients with indeterminate colitis) remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     OCT of the bile and pancreatic ducts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of OCT in the bile ducts is still being determined. At least three groups have described results of in-vivo OCT of the bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The OCT probe is inserted into the bile duct via the accessory channel of a duodenoscope. The flexibility and narrow caliber of the OCT probe (2.6 to 2.8 mm in diameter) permit relatively easy cannulation. Nevertheless, cannulation with the probe was attempted after sphincterotomy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first study found that the connective tissue layer and underlying retroperitoneal tissue seen on OCT were similar to those seen histologically [",
"      <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/35\">",
"       35",
"      </a>",
"      ]. However, the authors found that the resolution of the images was limited.",
"     </li>",
"     <li>",
"      In the second study, five patients (three of whom had malignant biliary strictures), underwent OCT during ERCP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/36\">",
"       36",
"      </a>",
"      ]. Of the three patients with malignant disease, one had metastatic colorectal cancer and the other two had cholangiocarcinoma. Regions of disorganized microstructure were believed to represent metastatic cancer based upon the similarity of images to images acquired in patients with esophageal adenocarcinoma. OCT images of cholangiocarcinoma showed villiform papillary structures not seen in patients with benign disease.",
"     </li>",
"     <li>",
"      In the third study, intraductal OCT was used in 37 patients with biliary strictures to detect malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/37\">",
"       37",
"      </a>",
"      ]. OCT criteria for malignancy included unrecognizable layer architecture and the presence of large, non-reflective areas compatible with tumor vessels. Thirty-five of the patients were able to undergo OCT (the remaining two could not due to tight strictures). Of those 35 patients, 19 had malignant strictures, and 16 had benign strictures. When both OCT criteria were met, the sensitivity for OCT was 53 percent, with a specificity of 100 percent. If at least one criterion was met, the sensitivity was 79 percent, with a specificity of 69 percent. When the results of OCT were combined with the results from biopsies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      brushings, the sensitivity increased to 84 percent, with a specificity of 69 percent (the sensitivity and specificity for",
"      <span class=\"nowrap\">",
"       biopsies/brushings",
"      </span>",
"      alone were 67 and 100 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is limited experience with the performance of OCT in the pancreatic duct. An ex-vivo study described OCT findings in 10 freshly resected surgical specimens using a 1.2 mm diameter OCT probe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/38\">",
"     38",
"    </a>",
"    ]. A significant advantage of the 1.2 mm diameter probe is that it fits within the typical transparent cannulas used during ERCP, which should make probe insertion into the pancreatic duct technically simpler. The normal pancreatic duct was visualized as a three layer structure: a thin superficial hyporeflective band corresponding to the epithelium, a thick hyperreflective connective-fibromuscular layer, and a deep hyporeflective layer corresponding to acinar tissue near the duct. By contrast, adenocarcinoma was characterized by loss of the 3-layer morphology and multiple minute, non-reflective areas. OCT images from inflamed or dysplastic non-cancerous areas often appeared similar to normal, suggesting that OCT may not be sensitive for precancerous changes in the duct.",
"   </p>",
"   <p>",
"    Laser therapy is becoming widespread in medicine and surgery. Control and dosimetry rely primarily on visual feedback of the thermal effect. The potential to use OCT to direct surgical ablation was studied in a rat model [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/39\">",
"     39",
"    </a>",
"    ]. One group used OCT as a targeting method in a number of organ sites. An argon laser was directed against the tissue. OCT imaging was then successfully used to assess the thermal tissue damage, suggesting that OCT may have a future role in image-guided surgical procedures. An ophthalmological study suggested that there may be an application for OCT in monitoring photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/41/7831/abstract/25\">",
"     25",
"    </a>",
"    ]. Photodynamic therapy is currently under intensive study for ablation of Barrett's esophagus and esophageal carcinoma, and there may be a future role for OCT in monitoring treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"     \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optical coherence tomography (OCT) can be used to obtain high resolution images of the epithelium during endoscopic procedures throughout the gastrointestinal tract. Current resolution is approximately 20 micrometers, which is sufficient to resolve architectural details such as glands and crypts, but not nuclear dysplasia.",
"     </li>",
"     <li>",
"      Early studies have mostly described features seen in normal and disease states. More recent studies suggest that OCT may be sensitive and specific in diagnosing Barrett's esophagus and in staging superficial squamous cell cancer of the esophagus. OCT can also distinguish adenomatous from hyperplastic polyps.",
"     </li>",
"     <li>",
"      By demonstrating areas with worrisome architectural features, OCT may eventually assist endoscopists in selecting appropriate biopsy sites when performing cancer surveillance in high-risk situations such as Barrett's esophagus and ulcerative colitis. OCT may also assist in staging superficial malignancies and guiding decisions about the appropriateness of endoscopic attempts at resection, although the 1 to 2 mm penetration depth may limit this application.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/1\">",
"      Fujimoto JG, Brezinski ME, Tearney GJ, et al. Optical biopsy and imaging using optical coherence tomography. Nat Med 1995; 1:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/2\">",
"      Tearney GJ, Brezinski ME, Southern JF, et al. Optical biopsy in human gastrointestinal tissue using optical coherence tomography. Am J Gastroenterol 1997; 92:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/3\">",
"      Tearney GJ, Brezinski ME, Bouma BE, et al. In vivo endoscopic optical biopsy with optical coherence tomography. Science 1997; 276:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/4\">",
"      Wax A, Terry NG, Dellon ES, Shaheen NJ. Angle-resolved low coherence interferometry for detection of dysplasia in Barrett's esophagus. Gastroenterology 2011; 141:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/5\">",
"      Das A, Sivak MV Jr, Chak A, et al. High-resolution endoscopic imaging of the GI tract: a comparative study of optical coherence tomography versus high-frequency catheter probe EUS. Gastrointest Endosc 2001; 54:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/6\">",
"      Hsiung PL, Pantanowitz L, Aguirre AD, et al. Ultrahigh-resolution and 3-dimensional optical coherence tomography ex vivo imaging of the large and small intestines. Gastrointest Endosc 2005; 62:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/7\">",
"      Chen Y, Aguirre AD, Hsiung PL, et al. Ultrahigh resolution optical coherence tomography of Barrett's esophagus: preliminary descriptive clinical study correlating images with histology. Endoscopy 2007; 39:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/8\">",
"      Chen Y, Aguirre AD, Hsiung PL, et al. Effects of axial resolution improvement on optical coherence tomography (OCT) imaging of gastrointestinal tissues. Opt Express 2008; 16:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/9\">",
"      Wong RC, Yazdanfar S, Izatt JA, et al. Visualization of subsurface blood vessels by color Doppler optical coherence tomography in rats: before and after hemostatic therapy. Gastrointest Endosc 2002; 55:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/10\">",
"      Yang VX, Tang SJ, Gordon ML, et al. Endoscopic Doppler optical coherence tomography in the human GI tract: initial experience. Gastrointest Endosc 2005; 61:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/11\">",
"      Li XD, Boppart SA, Van Dam J, et al. Optical coherence tomography: advanced technology for the endoscopic imaging of Barrett's esophagus. Endoscopy 2000; 32:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/12\">",
"      Faber DJ, Mik EG, Aalders MC, van Leeuwen TG. Toward assessment of blood oxygen saturation by spectroscopic optical coherence tomography. Opt Lett 2005; 30:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/13\">",
"      Kobayashi K, Izatt JA, Kulkarni MD, et al. High-resolution cross-sectional imaging of the gastrointestinal tract using optical coherence tomography: preliminary results. Gastrointest Endosc 1998; 47:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/14\">",
"      Bouma BE, Tearney GJ, Compton CC, Nishioka NS. High-resolution imaging of the human esophagus and stomach in vivo using optical coherence tomography. Gastrointest Endosc 2000; 51:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/15\">",
"      Sivak MV Jr, Kobayashi K, Izatt JA, et al. High-resolution endoscopic imaging of the GI tract using optical coherence tomography. Gastrointest Endosc 2000; 51:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/16\">",
"      Boppart SA, Brezinski ME, Fujimoto JG. Optical coherence tomography imaging in developmental biology. Methods Mol Biol 2000; 135:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/17\">",
"      J&auml;ckle S, Gladkova N, Feldchtein F, et al. In vivo endoscopic optical coherence tomography of esophagitis, Barrett's esophagus, and adenocarcinoma of the esophagus. Endoscopy 2000; 32:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/18\">",
"      J&auml;ckle S, Gladkova N, Feldchtein F, et al. In vivo endoscopic optical coherence tomography of the human gastrointestinal tract--toward optical biopsy. Endoscopy 2000; 32:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/19\">",
"      Zuccaro G, Gladkova N, Vargo J, et al. Optical coherence tomography of the esophagus and proximal stomach in health and disease. Am J Gastroenterol 2001; 96:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/20\">",
"      Hatta W, Uno K, Koike T, et al. Optical coherence tomography for the staging of tumor infiltration in superficial esophageal squamous cell carcinoma. Gastrointest Endosc 2010; 71:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/21\">",
"      Poneros JM, Brand S, Bouma BE, et al. Diagnosis of specialized intestinal metaplasia by optical coherence tomography. Gastroenterology 2001; 120:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/22\">",
"      Evans JA, Poneros JM, Bouma BE, et al. Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/23\">",
"      Poneros J. Optical coherence tomography and the detection of dysplasia in Barrett's esophagus. Gastrointest Endosc 2005; 62:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/24\">",
"      Qi X, Sivak MV, Isenberg G, et al. Computer-aided diagnosis of dysplasia in Barrett's esophagus using endoscopic optical coherence tomography. J Biomed Opt 2006; 11:044010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/25\">",
"      Evans JA, Bouma BE, Bressner J, et al. Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography. Gastrointest Endosc 2007; 65:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/26\">",
"      Zhou C, Tsai TH, Lee HC, et al. Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos). Gastrointest Endosc 2012; 76:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/27\">",
"      Hatta W, Uno K, Koike T, et al. A prospective comparative study of optical coherence tomography and EUS for tumor staging of superficial esophageal squamous cell carcinoma. Gastrointest Endosc 2012; 76:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/28\">",
"      Westphal V, Rollins AM, Willis J, et al. Correlation of endoscopic optical coherence tomography with histology in the lower-GI tract. Gastrointest Endosc 2005; 61:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/29\">",
"      Masci E, Mangiavillano B, Albarello L, et al. Pilot study on the correlation of optical coherence tomography with histology in celiac disease and normal subjects. J Gastroenterol Hepatol 2007; 22:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/30\">",
"      Pitris C, Jesser C, Boppart SA, et al. Feasibility of optical coherence tomography for high-resolution imaging of human gastrointestinal tract malignancies. J Gastroenterol 2000; 35:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/31\">",
"      Familiari L, Strangio G, Consolo P, et al. Optical coherence tomography evaluation of ulcerative colitis: the patterns and the comparison with histology. Am J Gastroenterol 2006; 101:2833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/32\">",
"      Pfau PR, Sivak MV Jr, Chak A, et al. Criteria for the diagnosis of dysplasia by endoscopic optical coherence tomography. Gastrointest Endosc 2003; 58:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/33\">",
"      Shen B, Zuccaro G, Gramlich TL, et al. Ex vivo histology-correlated optical coherence tomography in the detection of transmural inflammation in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/34\">",
"      Shen B, Zuccaro G Jr, Gramlich TL, et al. In vivo colonoscopic optical coherence tomography for transmural inflammation in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/35\">",
"      Seitz U, Freund J, Jaeckle S, et al. First in vivo optical coherence tomography in the human bile duct. Endoscopy 2001; 33:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/36\">",
"      Poneros JM, Tearney GJ, Shiskov M, et al. Optical coherence tomography of the biliary tree during ERCP. Gastrointest Endosc 2002; 55:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/37\">",
"      Arvanitakis M, Hookey L, Tessier G, et al. Intraductal optical coherence tomography during endoscopic retrograde cholangiopancreatography for investigation of biliary strictures. Endoscopy 2009; 41:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/38\">",
"      Testoni PA, Mangiavillano B, Albarello L, et al. Optical coherence tomography to detect epithelial lesions of the main pancreatic duct: an Ex Vivo study. Am J Gastroenterol 2005; 100:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/41/7831/abstract/39\">",
"      Boppart SA, Herrmann J, Pitris C, et al. High-resolution optical coherence tomography-guided laser ablation of surgical tissue. J Surg Res 1999; 82:275.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2675 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-9070587B58-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7831=[""].join("\n");
var outline_f7_41_7831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TECHNICAL ADVANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OCT of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OCT of the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OCT of the colon and small bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OCT of the bile and pancreatic ducts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2675|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/50/35620\" title=\"diagnostic image 1\">",
"      Barretts esophagus OCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2675|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/59/6064\" title=\"picture 1\">",
"      OCT catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/43/6834\" title=\"picture 2\">",
"      Normal esophagus OCT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=related_link\">",
"      Radiofrequency ablation for Barrett's esophagus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_41_7832="Poison oak";
var content_f7_41_7832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Poison oak",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7832=[""].join("\n");
var outline_f7_41_7832=null;
var title_f7_41_7833="Annular lichen planus - penis";
var content_f7_41_7833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76913%7EDERM%2F53806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76913%7EDERM%2F53806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Annular lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 306px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEyAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDz2ST0qjPKQSSaknJxiqFy21Tle3Ws+ZnXKKKV9dFsqDyfWqCAJMwYEOg3Ag8E1Dfz7GA25yelSCFJWjkclXXng81ojmkdDAuLVpCcso5561dtQr2QkcZmPQ5HA9Kybe8iClXVxg8KO49DVoSS3RdlEMSsNoQ8jHr9aCLvYp3ksUc0e75nRvlXrzSteSMSqxfNL1bGMY6VK+kysv2qG4gY78eW2M5H05qWKGf/AFU0YSJzuGP1pa9B6dR0MshhO+zkds/K+aDLeIDGIQjkfeccg+gPY1ctmWKPMxZkzhWfK/SrkMQuSFdpWDNkktwB3xmnZ2FZXMV72VplQ8Oc4LclzVhr+aCMB7Yt5gwWHJ/CrotLm382FFEykYBkQMU5yNrVGsVxP5sriJWU5CMcBqLMa5SKK8DeTGyBFUYIcHJ/xq+upwsWX/R4VC4CqDz7+1SRwy3EcKi2WNShdWikBYfUf0qrNY2720pnzDcjhQy/upBjnn1ouBZlkzGVDq82wZLADf8AX3qSN5An2aNiwA3BYflJPUEnvis61sniSB5WaPfHkP8AeU+2RUjx3FvtDyKpdCwVm4PuKBbGzb27Gx837M5453PuJJPWo1X7NcSSfZ8cfd/iz3qnZTShoyxaOJBg7XPTtWg7meYhkPUbSxIOatRuKUrDUmQOJFTBbg88/jT5H8uQMhAkVt0br6Ecqf6GqErtE3Dd84FPdy4X5yu77o681DVhN3Q66kR40nhRg/8AEuMcev1rKvCIiZVBaJj8w7n3q5cSskLDYGLgZx2xxUGAknl4xGwpFoqLL5UjKzsYW+42eR7H2qvco4uSoUKHBBJH3T2phh8u4eCRsqCMnPY9DT5zJHbyrNIm1CHilweMfwn6+tCFLVGBK7yLg/KyHGNvBq3pF48EUqQNtMjbjsX5j7buw+lVJFMczNjBZt3I6U60uDDZziKIvtlULJz8zn+AY7UxdDQhgk+3pdXaFYoocovsO5/HNaMLCadI3mCIv76UxjJJYcCq07SSaX5Ep/exRlCQMlwW3Yxjt71LZL5sKS5k8uYYhUgR5APc+tGw1qaLypbjfNNJEvA2xj52H9KRW+zyO8m5wi7lUnJQeoqJjELyW3zI77fmkIzj0+mau22nx4TzUeJRj5wxDevPqDSKH2UzOA0caMj8l5DgkY6596gmZ7o2iPuS12tMiKeNw+UZq5vMihWClD907cE46Vk3U0kFyqWojLy7lVT0Xvkj2o9Soo0pLtorwQLbh59q+YXOQo9SOxq3Mkbo0sbSfe+VQvJ/wqraWL2NudrSPLxJLM5yzs3Vie/07CrceHAg2l85dhnlDii5aQ5POwzksMsAQF+9jsaaGAnLAb92ApI5B9qnLsI1QOfM5KqOoPrTphDHDtjkf7UDlpgwKKuO3vUrc0uUdRmjjmMdrDIkwOFTO4I568mqNvYlSzS/vLnruc4Bx7Vs20CJIWkO5uinPJJ7n3prESJPFsxK53M+SSQOw+pqib9imWlhDPvDsdrlTg7vY07Zm5WNG8oFPnH3uD1wKaS961tG0Q8yJDucL8zDPGfcU+6l+eE79qqpBcenvTuFiKOSCGQ3Fq5kQkmPcvBA46fnSwqMGJm3NvyrrxyR3zVPRWSNLd3RJBGSw5IyCTW3p9k9xDLOJfLjZ/uDqR2P07VUY8xm2kRW9uracwldTtY9OoA5z9azr/zGtJJoEeSMnKYAGM1uTWptZ7u0kRGEceWUEEHcOCD+NYkSSSWklkZo4Y8lmcHsOmKp6Mm+pmNG814Y2fzI0yWYnlXA+4D6VYgctIhfPAyNx6AHt+tSCGO2s1MbK+6KRyuCRnPU+/vT7e38uG2Hms2YjlR2PXmos+oN3Iy7PPsR0IGXDk9R3qNDsJQsrhWDKaZNKIbWeaYNiPcCdvB9qcEK2i3BAHTHTgADIoEWbDzBFPsePdHksvTg0+AoFCx4Xa3IA9vWgQr9qTfklkO3BxjIyM+tRKSsTYSPg5+b3oFYrxTvcXSRyL5UxD8sBh++f6UauitBLM8LbFHy8gHI64PqDU0lrDdRLHOCTkgENnBx2PpVOQTRTLA8sbwjLKZlOAR24/CgLdjKF3e2gitZpmu4khB2yKXPzDkc8jH9KytdEbWb3FtaNC0Fwr+YPmQl16Z6jlSQDXRmG2DRS3ctzaKJ8eZZxiRgSPu4JxwayvEMljaNqNtZXFxcW19bqwe6j2MHVwcgA4zjI6UrAbE820Vk31xkNg4q1c3HJz2rC1Ccljis0dEpWKTTeZeIDnFace+KLaNxY52kisASE3Ua8kk4rqLWAhAWwx27gCeaswkO0sNHCRLHIJGHDuuea07W6JglSRmjkJ7Lz9adAJ3t2QxYjOD8x5JHpToYQ0n7+NnAxgg4I9D70xDRM6+XsjJZwctnlvwrat4hNBsCgBByScYrOgKTrKIQq3MS5cMcHjoPxrR0W8mj843FuCzjAyOn1FK/YaJhYrJbJHARJI+e+SuPalsbacQs06tJGoIDZ/pSE3UJR4UgbeT8qnaU+lSafetJDNDPtikIwNy8j0qW2Xa5s2bxi2IKICO+MGgwLcW5KWbSMgIYscDr1xWOLqVkZnYBkHPyfeA6muh0zyp0kklmYLtAEkZyGHcEe1CbWoJLcyltvsyRSR2yxiJjuYIG6nBNS3NpdXsKtApuIdpIBUA7fT3/ABrV03URaSF7SfzHXMZRlyrqR15qB8pKMfIwJbarcEH0xT5hPXoc9HaRJcOTEkMBBG1iR5Z6ZGO9MhtIWtIhkTPknzDJ/j3966WeUA7hBEfMwm5l5HvVK6t90lzANoWMbyW6Be5FO9xJFG2jDxEOvyEHcCRjPbHvUq6ak8F2cASRr5gYycjHat2Lw/OuiW94Jo3SY/fjOVIB6Y7Gq4gSFvMnVkgYYOwchj0zWqi7XE0nocqzm3BMynay4WQ8g1BNeW7QxGFmkckn5TgD8fWughtpLqBz8zYByqjrWBfW4itnEAEMZG0qBwD64qGTohu5Y9js4bjadp6/41CZY3fgPwfvdsVFnfbIxkVjtAzjH6VcskW6QQIyC5I+VDx5nsD60mgKepBRGssWGbG1h2IpkNwixOGQPE67TG/IqN3SISRysqHcVG/ufTHY1mXdwbeUwGQLvXcr54VPU+9ACNHBaXVxbyXQjtUQyxZUv8zcBMj+dT3MLWjWNtsaKRCJxg/xH+L8OlZd9FE99b280kvksiyM2NrFRyT+QrTs5ZL+/aeVfnuRiEdMp0AHv6igC8ZkW1lLBhKEwzg5B/H1qTzDdxW0EmxjKodmByyLxgA+tS3SiLS7I3ERbzrgpEit/rGxj9Kj0Hdb6VLPdHMkEjIobqwHTA9BTY1Yt6dGyrMzkzR7yAR12jiti7dprdRJMWkKgR7uM47flVLSYmhtUilDZdi4LnP3uSP1qzGom82Od+Yh8sI6y5P8hQUR3FyyuHtlVcHA4yRmq9xZeVHLcSIzzhgxccfWtGO3HmmMkZC42IPlQjtzV+WxJtY5HmcuRtMeeNhFFrlx7lc3BFi0ML4X5X4TP5n+lRTpGJZGZirMu5ZCOvscVX05JnS6iQDMLbHG7qOxNSXLbrYxwMRIg5cLnipL06EsbSRl5IJRGyrtMink8fc/GliMMUZDKysFzkchwfWnokcsDBEA3KuQTyRWjpFql5qOnW+4xLJIikkdSTz+lVFXHfqVIp0d9xZMoMqwXriq08uMRr/qWYEkDoe/HbFdX8QtCttLctZRPHIJnjk3/KRgZziuV85kuHlkzIZEG7BGN3aiceUSakrooWU6T2C3ClmuA5BULj5QepNN1Rd8TQ2aPtkUhyoz5eetVNDJOjQcr5zNJ37buM1oiPyRuiLhmQ+Z2BPbikFxbbfbwQlTt8tDCEK/eXpmt/R76IpFbxkqyxOhk4OQB0welc+rXCx2rTFzCuQMHBO7tmreww8vImVGCSpBBGcj3q4StczlFMjdVhkVSTLKV3j5sZPpk1m6lHO8uCYlG3DYA69quTJIZw7rwqbgVHGDUU7s+JJG2uMJgD73PX6+1Ju4Wsw+Z5ANwUmIR7V4HHJz6U/Z5xglQoDh1YHAAwOtJI0yxIBu3InmEr1XJ/liqNw8lwjRIrI4lTjHr1J9abJ3RSuyLy8ktUI+yLiVgP7y4rRbyzEpPzIF2j5cc/SmLDHBJPGXYhnBZlGCasBsRE7y3cA84xUpMfSxE+T9mMIYk/KzZ5yDxRe4N/JEgI2qHwegPNBR9kJAZolOW/2c9zVp4l89JCrATJjPXnpQSQ24EjAxM25o0dRs4681n3l1Ml9IsNtNMsaFt20YHqatQ+YJG3ORgsiY/hyOKyvLjl8pXVhcTxiNnd85bOScDt1oAqyWX2i9TOYxuDEQybsMRwQehNZPiaJ4rW3+1OsisDs3Lt2kHBziusEYiuYwyqqBcDHoOMn+dYutskiI6kSRQRuF39HPdfxoEV7lid2T+VYl9IFBJPNacsoGecn0xVFrVZ2y+SPSs0aSdyDQIDcTPNgMQcLntXYaZbxxlWmlPKbRntWPpdsolVEIj545rejDQJGjqHdif4eMe1UQa0RtZbQh5SkiqeR3NRNI6iaRvKM0pVAu3GBUNxD9niimgCusoyydDnNPkheR2mAaCZe2chqB2uNtNPW6vVkmZ42ztZ0HT6+1WZCzSthhJKAQJF53AdB9avWQuJtPkUho3OGBj7mnW2m4iFxdL5bMwUIBzj1NJIRVsrgXFlKqvIkgOTE8XPvUGp2rCwF1byyK+/JVgMEf06Vr3unO9wHgkUovykL1I+tPmhZrE20giHOQ2MEn+tO1wV3sVovtV1a7Y8ElMdOF6elNe5vNPVI1MEbO7ABRhSCOTV62heFV8s7RwCFJ5qB4o47sTTu8ycjyWHBJ96TXQtKVyaJYnWIyzMhX5/lHt0rTtWjXZcOvnxHlcgiseWGeWzEIGUHIDcH8DWzo0VvqNo9pPdJBfKC8CysVDj+5nsT2PSkoDu0i3qFpay6Sl1DNF5jsVktgxLIOzeh/CsdoAkDIzkrIvHzdq0LwJHbRWyK8ZOC29cNuHUHH5e/WtTVbvTtSs4lQWlnqEDeWkS5XzExnOD15zVJa6kvyOetrW4XTZJG1B40UhDbq3BB71dSado47TyYdoG9JVbJce49qypmeWVktY8scYQtzj6Gq7SNbOJWlzIT8o5wp960U7CcNDqNJhjXWVjDRmCRCTvJGWrlfEgWF71WdVU8BB0681rW0zTWMTl1Xywc7R1JPHNUNcsllsXEZMkg5L49e9W2pLQy5e5yMqljbTkllXHmIeMr9amYAxSiNFxOMY2gH8D1pdsZj8uPJ8oeWQ/3jjqaqswhnlibIDfMgbqD3+lZMaK2szzXUFvPId8iTAu23JbHGD+FYTXcUheQBZlST7g5yuemPStm6cDdgMCVDcE8+pqpcQrdCeG18tGliA3HAyQeST2pDvYq3Vzc6lqBmu1QecgiVI+Nij0/D0rdsbZLzd5p/0dDnIfaYwO4PY1izXrXcscEQEdhB+7jGerkYZh7GtSG3JEMcSGQ4JIH90cZxQMS6u1NuftrPJhwYriNTgAHuOgz3rbiH2jbgRANIHZIzvBJHVj/So3vSheJbZpAyeXtXDA8c5xxU3h/QkntpblIEib7o3ylSSO2BRq2NIuzzJbW80shjBjbeoZsbvYCnoWvpIJhF5NoW3gj5ZCR/TP51UtbS1W6V72JN+4qsbDKs3t61ru7gMZioiwQcAbiT6elFyktR15I9uZA8nm7xuBHVc9//AK1R2VzsLYcAYAZyckDvx2pkheaGGOFvMkzt2lMtj196VVWATxhlCucjauBIe+PWpcmapJLUz0eNtcu5I/MVCoJyeGPpxWnsMSiSIeXJ90qvRh6VRZFttbttpVonQpk8DPv75rUhDSPJuDRSHBAP5dfWhDS1uCwpNaI6kKfvBv7pHapbefyxGw8yK4gO9WUZyexzUXkqol2kgKfu9PrSK7xzT+XG43qAkb9yfei9irI3Nb1fUddu7dr9xJIoOfmwGGOWPqa43WLxbe1MqqxkIMUCY5LE4HT86tTySyrHEZp4Y5DuwGAUHOME9ajsdLT7dKzk+ZnduALDA/pVN8xn8OwfZFtrdLeR0MsaLuwchhjgj9alkJ+0IY4VyiKCM/e46/WnlAkm7zDtUFh8vAA7e9LvfyQ6lsbN7lgMOfbFNAokd/OsrOiBvJ3IVVhnbzyQfrT7uF0URr0ycq3OT9aqXREZAAL/ACj7q5yO9W42maKNsIqcqEHVlI7e9KPUTRFNHGDG24hygU5OOewpNjSIZVAOxguc+p54pkswa28orjyCDkg7s+lWpFEdjFHERnkse5brz/KnEGRmZo7tmjWRhLG8bcAgr+HTpS6Da7bm9Yv50rRmXJHAVem339qp3B8qDz4CwZWGRnHHqKsypELMhhtSToEO7OD1zTuYsrWro1zMJQROPnVOzKc881aRM6dJH5uGQYYkDn1x7VS1KN4rYXcS5mhfcAOSyjqMemM1PYpHMGXcCXUlCxxkdeD0pJltFeVWiszKdpIXDSBsjAPHFXL+KO1tba7ZmYTOGLg8bScDHpTLSDNrdHy84+ZU9j/9fioruWa50+GITGGS3QINnUAnI9qHqK1yrBexw5kaOR/LkLDKFQWHXOevHPFQwW7ssNwET7QSXAA6ZJ+Ue2Pxq/Yq+6Y3DtPKxLAyfNj6enUUXY8iFjtcBHBIKlTihiKF6CE81cjaoOD2GcEVk3ytJLbQKUCmfJJGDgitlVaWG5ZZfmEa7g/VueRWRq0kUlpaXCyFbkTAEkYG31AoE9Chf2hVyyjjNQqAkOQvPeuivINynK5+tYsdqZLgxDhV+YkelZmjQaW9ulxNHPIVYEOnBwfxrs7r7LFDazRvFJHIgZGU5IPcGqNu8NvaxuiBxkB0wMkVZj/eP5cEIESHcBszjPvWiizO5NcW832RblofL3NhC4wG9qI72KExTGJ1GMSRt8xRvUVajkmZIo3JjRFzlkzj8Kgk1EbWBEczSAggxD9KfICbvsX7fWrF5WkLiQt8xMQ+72wR2qe815bix8hLedRIw3EIOPxqpoyiw0yZYLe3ilkOT2b1/nSW93OuWkhVo9uCVOCPwoUGMt28qtbgrE4k3bRuBBrX0fTH1C6SSdlRfukMeBXPvqUc6rItqUlibiRScsMdxWvpNy11pMyogeKYlsnIKj+lXGKT1Li0kdXq/g63t7K52ytHJERuVG5CkfeHqKzf7GtrXzIPLDfLkbx0Pqajillt0jSW5ZkIx/rM8HtUk2recsJkVZERjuKff5459elaWW5mpy7kU2nMYUaVMRspZSp649qx7qBpI402hZVPyS7eRnoM+ldPb3FhKCb66dFVSQqry3tx60muR2cM9i8F0t7a3EXmOtt/yzPTac9SPSoqJdDSDdrM4Nbq6TUYoL12EQ9Djc3TrXS6rouqTw2/2e3hIcfIRIrsB+FOu9Otp4gNyNDMxVVkxv8AqRVGbRzYxGBZWtmX5Q6knFYRa2YnuY2oaTdpcxnIR48ghs/oaz2E88gguXChMFgx9OtdGPtUCtDdSJNwBFuzh/x7Gs64cxzbZkEasQAccZ/pTsmJtlizjkSJztKNKQVdjkFQew7Vekl8uRTGy8jDZ4zWfZXF1ElxdeSNsBCqF5P1qFJWuHuJNvmMwBOONgqo6Mm1yhLbp9q87ywTI+Bluvpz9aXXtKc2ouU6A8nOdpqRTK86qUYsJhghcqMd63b2VJ/MsVaPfngleB3rZKMjKpJwseaqwdwJQ0fzMCx9cdqzJi0ELxknc+Y1IA57k8+1bOtwCHU44xueEMZDt5AYDGR+dc1eq0d8XEjbZRhgw+Y9vxrB6Fx11JrdCzQRsAecvsHQe/1NdRaRSR2jXKz+TLJ+72AfMsXue2fSsi3D2dvKpVBc3GxFcdUjU5P5mteHdHGU6ljg57mpKsTW1qsixogZWVtwZDzkc9a2IEBWOSOUNG43DnvnkfWs+BWW0XhfNzxk9CPatWzcW7IwiQRSscEDhCByPxqkOzKV1bszxTQxGQ27s7Ix+bkdR7cVIupWjzvA8jRjy2ZVk6qfTNWbp0RfNZVQsCASec+n0rLnMc0TNNCscZGx2Ay5zx8oqNjRO6NVbiOzhi2SxS3kyYBRgSq9cH3qNZI5Eje4uI1eM5SNnAMee4qiLEXKnyQiNKVypgViGUcfp1qyLCcjzYpLWMuMAfZeGPvSSGTXN1Bvhy8UrAjO1uPpU8Nwu4K0iybRuGX+8Omaz7uK+iUJcRWRAkVQAu3P0pL0ARSyPom0qFhUxOCAe5pvcpXNWN1IkdShCMoKnJz34p8cqSSukx8onMke05IYdB/Ws228u5khWDTroTP8m1XBLvkAcZ6c0yNE+2TRzWskckcpUlshVK8HBzz0psb1Lx3YmBbzZWwCc5H/AOupoHksrRXkdvIfcgMbc7T2xUMjJ57yyiNfm8wAA8+lQxmKZ5iWYncNkTEjIJ7UxcrZYVJkjBiJTYjZct95cfLxSQosBInYiApnA5+buKekhtoy7NuCuFMWdwODyM+nFNcr9pjL+QtvKWm3ytgAHqPwo2DUhuOFCzxOhRQdxUAc85+nNHlYKJEFbIUqzDBVq0SYo9NzC0rG4Xy5vNXOB/CV9sCsiS4lvTZ2szJ9pl3IHRMAY5ycegFD0EmRwfvpPPkzmSZgrHnJFWvLQRb5ckqxGF7HPFVrVIlhwgzFCMOQcck/ez71a83yo5I4mCK7DeSOAOwpoCpfPH5cP7pfJYFZg3JXPSpLGJzGlvEj/MN6kDgY6morgGeGOIxjzJHMe5OPlHOfrU+nzssSmN38wRmNSWwSD978xQTyjwWjDxKv73lZOmMH0qOyjjt7WaHa2wHuMgH2qOzCpMyybkB4JA5BAxmpSY0na3K+YJYwOWwN3r9aLdRN2I0kKXkhjIMjoM5ORt+nrUcSGWafOGbZuIzgn86hulmXUFgt3kQlcOd38HB6+uavMYbqIysTFP5btgHqQelAupVgtZPsk/ksflbKkHBx1NWtQnS6F7Ok0uS4G2U5ONozj2yKq2wjWWQo22VDhVz1BHepFMPl3UMqskqhirBuAQeh9sUPQkzonc+YMKPPAXk42isy9hZrWBWyCCyc44960WHmRjaMq7qOTx+NVtZZ0sLR4Uzcmbyiu3gdiPfPFDE9zVulVFIYkt/dA5z6VQXT/L3zkOWYfdyKvaPE1zJJcTuVcgBVzwPamuFM7cg9QM01BLUpu4+3tME7iN/BwR0+ta1vA8shtrfLFMtIV6fj61FAm6MxxIQNq72K1sabI1jAXtpGSe4UpleGC9wfY1rEkybyL5UGCWxgkk4/CpLGyigthcOC0jNkHrtx7Ul6GmvViQ5XblT/ADrXOYLXy40GSMhsciqS1KeiM2ZmkZpULGVznk4x71SdJMBSykkE9a0W3iJg7MS52gEfrUdvCTtkHCkdD3qrEp6GXLGVf7wRgO3epNPlubacC1maMPw65+VquXttI8OQGKKc9AAM1VtoY1LjHz43Erz+VRKOpa1Rdk1O6kcrMAcjAUKAfSpre6njB8pHQryWJFQWduXdZUWTYg2jdyTnvWvbWqG3kM0oR1O5Tj5WHpntVJGdrClYpsS3DpvIwY+nPrUOy4DkwxNEp+YE5AP4elWILqCKWN5YVmhAxtK9/UUlrdmW5EDykoMlEJyevQVEo3L55JCvY3ZuLVpp4obaRWxM6k5IHT2ot7LVQLK6DwTW9w5A3HIGGx8w61ZcRBpAkrxj7xUnPP07VLZmawKGGYQTGQOkmcY4/XvxUqmhKpcq39lcWV5NDdISd7AGFgVVx1x2qvsaYlJFilLtgqR1Pp7Vpi6CQSnes2x8vnjB6cUyQxnwvKlpaqXWYfvM/OX68HsMVSpoG7nN30SwRxSQlxKrGORM43D0/Cqk11HDIWjVsbdrKDjJrau0dVZ1O6ZiCydj2Jqve6bus/NdZBJJgqf4nHTj1pOPVE3SMYSqtoVt1PmOCec/MfXNMC/ZtLurppC0qqpARuPerccVxAkcMrIwYHZggnryKx5YpJLSWBCEkIddmOMY6mpi3F6ilqUbiT/jzNxkJKHY/N0GOKotpunpPpsiCaR41d51Z8gnqCKj1Nt1vp6rIQmHBKgDoKoi5WS0uDFMPtIZU+YckHg4+lZt33CKLVoY5jeSySt5h2+UAuQ3POa2YJHGWCkSBlIUnisvT7c+QqqwjCtueQnOBnBrasoFu78tJcL9m8piXIIEm3oD6Z6cUIotwxhmkuF42ttEfGWJ7g/Wrj3kdnYohQeeHJCDqx7n6VRgEsl9bXs0IS2nLiOJGBCAHAwOwq/cAJEbqZ0Yg+WiKOQDTvoMrxxSyMHuNjuW6D7qewp7It1fW0LvsEasXyMrnPyk+oq5ocK3V4sUrhET5XYfTg4qaVY4rgj/AICHx27Z/GnyaXKv0IUeMlZo3VZF4YdNx74qxHOExEyyCPO8OOQB3zSTIG3o6o4AyRnv7VnzSIttcRwvIyfwxl8lCeoPrUaoq1yzcyhCD5imPduIxkH0+lMaV/LCTmSLcu4k/cJqLT43udOWaD5kEZaVFGdu3gkitFB5cgEx3pGgKgfMpz6ipSuXsN02Y2r21420yRTKNyqQRjkD86J5ZmmupZIiyuGLuF6E84x+NRbfLD4Z4MSLKUJPQjH3amtZGWRvPVHiOcsGwpx659qdwS6lGz2u4EiPJEi8IzYJ9waneEyQ2wj8tpA7ODjnAP3ajt4Xa0W5EoEUrEgIeQP6Zq+6hbtldESZEVlYNuJGOQB65qo2G9StcO7ECFi0ewyMAACjHqKpSLhZcRqIJFZWZxnYT7irbGF4l85HhkMbFZEBIdsdQemOenaq0JzbhDJ5jO+zy8EEE0NAmaUUqyyJBjzY4kVFlU5woHzHFZWnXM8Wq3OqQRptVTDDmHKhTwTj1IzUV15q3RsgvJCiVlOMLntjrmtbY8cc9om3yQU8uMN907hjmktWTaxTW33afMV3BGmPmr0B7jj2pPPkaCb7PsaJhtyU4Zvareou1zJNHcSFQ8paRQNpJ6cetVZ4BEyBI5YFUHZuOV6dadhMcIFgeCRiwVCCRn86bn/RlWJk8tyysuMkDtz6ilnnlYQSStgsmCR6E4xSzBEJiUnehIwxPLn0psEM3hZmkbIBXGQOSelVodsjvdMrjEvyqeflHBApzgKnlvvDk9CeDzT4Y45rQRxk7d7KGUkbGzzS3JGQNJNd5nO7KPGDtwSB0PHoKSWSVLvyJSuXbf8AdBXgdB9amfe15EJZiqb/AJO3OMc1XvZN0kMUaBpHl+cPztI4yD7+lC2AdMhN5DIirukZl2gepq1p8Im1sW0hMZnLW7GTBUMVx6+veolZm06a3uFjV45UdMnkg9f8aoSvLbQmblZraZZo2PKsA2c0EEbjyJIo5MABtjcnIIHX9DUsFubi6jt22gzXMdxbYfarTR8lfTJUng4zVjxekcfiDUQjxeX5olTaMAF1VuB/wI1nTTrarFIRk204vzzjdsU5XPbPSmxM2rZBFp7KqhixHzHqPpUEce6Zw5Xbxknj9aWzlQja7Hr061DqJMVy/kOXhHyoWG3I9/8APatZbBZo15Zvs8skbuVBIVyDuGO2KltLjdJA8+CIzscLxlfWufe45AK7SUGGzyrdKnurx2lXCFmfnevO7HaknYGXrxgs8HlgdThwevPFa1sxAiyCSQckniuTvZhG0WxvvLuKjse4q7pOomQ7JCAFIB+boO2KcJluN4m/I3llVkdDtQkLnOc8UlrGrJkyZWOJiQO5HemGRyqSxKNqA43Yx+P1qb7T5USkwqrNuwUXjJGMH2rUzSK8MCtaS7ASSjZaRyNox+VS6Dpktx5geNgEhVhxzj+oq35mbOb93IEKAcLxsxjj1Oa6jS50jt47W+kVJkjUxTAjDYHC/jn9KaBy5SuNCa0aLNuyCEKSuOY93Rj7ZqHV7JreR7WYwuQPOkVG/AnHbmt6+8Z2VlY3saxL9skgSAC4IY792Sc46cVzcup2+r6rLJJapBatFteO3b7zdS3PvipcraBFS3ZnGy81FQgo4QyjY2RisXfNvkaBFLQn5wTgmu8Op2sl5Pe6jbIzSwRwh0favmKeXYAdSBjiqs2l6dq/iK9j09GjxGrQh12mR2z8vP0pJ3NlO5y6SCaHeHPm5x5Z/wAabJclkJkTcuQCScYq7Y2oE0yNGyMMgo45U1hagSl3LGyHZnAxxk1bjoZNLm0NyyurOVSkk+1jwARnJ9KtSXUccO2J1BhOW4xkkdD6iuJQb5eDkryat297b+a3m5G7jPPXHcVCE2aq6gxZLeFGZslmkPRRikW5kuIfLhJkWMEglR61Uu3ktLbFuspHUKxxk9vwqS1b7Dp7i4Ur5gy2zkg+1CdiXrqLLEbWyVUBdHchX46+1cjq+qGOzQNgO8jxO6rlkHr71089wI4DJJuMQBfAPTjr9a5OG2ju9CjbKPJPK024j5kXP+A/Ws6u5SMu9WF9NiFpJtTcQrMeV9ePfrWfZwr/AGfGbYbcXTDzDyz4A4p2q2cw2Bpom6ZOOSvv71JpzeTbW8DRAQoDKxzg8/p0FZMZradAUuZJrZYyioVkDfMOf4vrVnKCJ0WUkIPvY4cDqc+tMiES2uno0QjkuGa63s+NsKn5eOpyfXiprJmeyVcH/SpGkyyfdQ9qQLzNHy0VVhkYhl2/KD/Djg1MWlt53+2ESRPgKyDJBHTNV4DBB57RcxvtxkdOMflWlZ3Uar1Tzo8AK3FMpprYrToYLlXtptqzIG3bud1akcs32JivlO8o2NuOSnPWs28hsJDJbkr5yN8rqMB88kim2OY72VjD5cUIjhmKnIYHJJA9wf0pp9Bo0ElYTSKCPN6lGIG76Go5ZdrQ7kxI5DBQAR+dWZbS3dkSNsKpwshOMrUO4QgxKUAwU2qvQeufepZqkrFTT5l06+1GMu6tMhCqmVHzsAwJq8xS2UQxgRxF/LLk5I9PwrGurkvdosZVktzukycb174PqK0NQeM3cMCbtkpAeRVzhcc4H5c1KdgtcktpJbm4kv5i8i8xrITnJUf4VDdzm5hksoVVkU72YMAQO/X8OKVZ2hsTa27AQK+4nbzGCMfrTmVY28m3ZdjHzYXKgseMc+3FPRjsW4VgQSf88mC7AzYAP909qoyqInVTI2wMQpOSEOeme9STyiKBhCrN5gHmoe7A9qZbLsklku4DMiAEox3BWPrTvYEiwqQmzJuXlABKqFzgZznj1qi8kpKJGuJIzvMm3qOg/GpYiLixIiXy7ZZsYx8yt6fSrkNusKBisTKkigo3JIzz0pN32BK2rI204W9gtxCSzwYeTghiD1+uOtTzNDJa2saHMvn7zL0B7nj06VJeH7PqGdxVyGYpnKkEYqjp0sSI0DcKkZCFh3JHFCdmJiPI9zOkjDDgnac0y+YzOG27SFxktlSa07YMsu63VJFC58rI3YOckCs24kEnPCDeSAOMgDvmruJ2Yy4uEhhhEkG0bcjA7A9akugwdJmyVlJ5z1JHTPrUJleVcOxZQBt/wFMuJWLwx73eFP3rKG4B/wDrUMlj7FC88yk4VI+Sw5x2pkSxmRUPmZ3BsZwOnX86tFld5HdyokjyDj+Ic/kaz5QyXDtI4K42H60r2ET6u7reW0b4Vgy8qMnIGaqSw+bepNI2E3jIB/Wp9UaQXsGxw4jX7+cLuI4zUVw7J9pRgu5VAcqMnJA6e1BLJCp81gdzRk4D4B4NVL8GS3DfMZAjIyhscdAD6D3q4kiozNIDHEuCOc8Yqi8avDM0jgMcKhxjdnk59qYjW8VO99qEzoZNqQ2xJljVSQIlHT0461zeuu/2VydhkdRHgejf/WBrflado5ZpC8zi0hSQs3C9gPXH+Fcx4guXk+2RzxpstmLcIA7OcADPoMH86lgzWt3KzBFbLYBB/ve9azL/AGhZttQMWDAjGcnrn2rndwARo2345U5zkDj862dLk2XW1i6q3OOhORW3SwlqihJtbzEVAG2h1GPmG0/NxV6B0eyIfcZoXymB8pQjr7Go76BiUeEhXVyp3HkZpsTsCvlnYSm0Ky4BYdvyqGBNcxkW4UBCkcm4L6Fh2qoUFveL5ZZkYY+YfjV9ImlguRkkRgPheuB3/CqkyATIWBwVB6dAalOzLhua9teI9skT7Qhb58Z+atEvGbH7THAERJf9WxyenFYdvbNK7COMvIEJCpkE49vXFP8AMcwolsQoK5LOchiOldCnoHJ7x2mhTQSyKLieSFJ4y4JXKjdxg/lVCa4W3hFvauhErFVduhwf0rItbyZNLWJpQZAcKx4CjOcN+vNWJfKutX8xbeSOzCrvTeXTdt5IIHFJ1NAVOz1I7a2mvZEkuRGN7FSd2VyD1zXQWcMUMbzAAbcBAO4zyMelR2cZaKDKoIo12pz+pqzd25EoikkQ4AUsjfKAec1mpX3FKd9B6Az7v3WxixIBGR/+qpbqaNZbWZppS82VkjUHgA8D6enpWdIwePAY5jQsXBwyr3FLJFKsdqyy7EYFc53Mo6ZNOMhpGqIrdbxLlVaRHYo8ecFhXN+M7RVkiyioqAMUU5I57mt0pbwQLGZnlCDLAHn8D2z+nSszVlW7VikIt4GwBEjFsfUnk11PYzt71zkI0bccgKSNyup6UwLvywZgyHOeK2TbLEJWAAUAFUTJJ7E1jKWS5JAyu3ac/wB3NQ0Nq5al1NZwRJGzBMBpXH6CnQXqThPIJCKOcLVaBkhl3yw+cmCro2Rz61OpgMSeVEyowJMhYAM2f8Ki9mRZFHxTdkW5t45HEsp8pMD73r+lNumtNPsoklKkpA0oJXoAOAarKklzfG5kCCEZWPqQF9RTb8tcea8YRgiF3LLwQOigVjJ3Y3ZKxz2srDd3unWMce0XJjMrDqoJ7e+KZdfZDPNFZrIto9w2C7fMEB2jt6c0x2kPiW0a6k/1bRyO6nB25AIH0zT9TMdveTeTHtIZlCZ98CpZSLNgDO88ys20YijVxjKqcAVu3kpthIWUqYztKZ7DtWLBE0Nnbpli+4KzDkDPOCa6DUAHj+1ELGGIYqnIHr/LmjoPcAVWBpAoVVVVXHqf51r6TaI+orb/ALuaWVQ5mzyOOn0rFNycWk9pO6mSaVHVBgtHtA57EcnNbmg2/kXru6ghMBiDg46Aj+dVBXYN6F6/sYZkihLKsu4Djrj2rKs4g0t3dpGBcLcbFGdwkA4wf1rauo/Pl87MaGPPHXOPT61mPpTC7UWlzdEXcxmdYXG0nHKkH7v1+tXKGoRZFezSPK39mKwjVsXDDlV/2c+p/pV3/XLE8Z3KOM7c8kcj2pt1bPp+lPatFs8qTeFTgSHsWPc0kxa0C7Aqs0IZkLZXOO2OM1m42Nou5RTT1kMxuI/KjkJCspxt/wBrmlsCHcyM++5VthAO1MDjj0rWt9Nnu7H7RBuMSsIidwOGbsagvdOuYDIhh2TxEh06Dil7Nl8yZXiZgZZI5CjDls/MM54GKghMkku1FXeT/FxjPVeP0p2PMWKZZMhAQAwGVz2z/jTIHNsqyKHW5VvNjdW9OOR6VKsDJGjijnO0iY5I5bAb3FSxOsNsrKPn5MitwSc5GPXFV5R5SxOsoaUguMj+I9Rip5blxHJO2QqFVMhOA4xgL65poYk+3akcJMTODLIGXgH0B7VKkkcZgfLeY7ESRkcNnnrUACLtIVZCr5YZyOnGfalaAvdpDIhSKRgMsT8vrg9qlILiTz/apyNowoO0M2CoHbPenmBpkbOPNQjdHnHNIsVuVSRlPlIx2lvmJwePrjirM8wkuGmiG75vnTuw/vCqsQy3pAe0v7Ylfu8EydVGO3tVSV1gWRpfnifO3AHGat6fcCeZFXjAIUk8msqJ1kmyz4gLnJIzyO1Miz6kUX3YJPtCADnbg/Ic80NFJI0siMT5jFnIHY0RIqzMQ4Co+4IwyCaUS/LJOhG0vtGDgD6Ci4C3Eu6yRU2DZx26e1VQ0U32qeaNnB4AHXgY61PM9uZrWS+h/d74/OK/e8vPPH0qLUliVr2O0d3azkaIuCAsi5+Qr6jBGfepe4kNvrO6/sSK9Mbra3E3lZDDG9AOPWor4bNVHAMc0JBIydw/xrQvNS3eFhpjoXWO6S8R92CrFdrrj9azpi3lTylHG3mNTyWz2H4VWwhRkhSkecdSRwB06VDbo0eEMhdwG4UdOamuAI7AmMqxcqgG87mzTdQ3QQlxvw6kDyzySP4c/XtTJLl3IUgiaZdkFy8ChwcIyR4znjnBOTz2rlNbAj/tAQTNNCs7FiPmEgYnGD7CtbWUmtYotPnVJZLcCE+UcAM3zHIJPPPOPSsW7CRxqgBcICGjHUe/vSEw8LzpqJhtZmVHUOvHBZvT8a2bO4XyYJAzt5Z2sWGTwfT1FcNFK9vcJdwk5BG8Zxj0Ndrp0zXFo93APLUv+8XZ8o9TVxYtmbusQkWzlWDeZhyV5BPas9JZBauwwxV1LJjjHY/zqaKRQjwuGQupCkDPT3FQWi+c/lOxw6kFsc/jUyGadukaXgQkeU/ykx9s9PbAqvOgRCB/yxZkZSDkr7GpbWRltoJEYiVPkceq9j71Yuo8XZdMypOwOGXBBI5P51JUdwti7S5tWIITjLc4+tXLaAJbyApA4cgCQg74+nbt9aqLby2MmJkyYkJLLzuHrVu0IeQ+ZIyFWznGMgj1o5mU9xfsMQlJLMSRtKSZIyOpzWxZFhaGN9sS8NvUdMdPpVUxCR5GtVC5XPlyHac98VZgjmcTQsEKqeQ45wO1MG9NS7FIZZGkdHCr8yMqj5j2z7VM1thMSKSzPliOB70KrmUhIxHHgAqGP6VYhK7PLKszZJLNwRTMn5FR7WB7ecb2U/dVVXIIzzk1UvbQW8BaNw6BfuoTlT6GtWWYSNngZ+XZ3P4UslsjbnVG83cEzn5W/D1oKi7bmLZSKcAMWQKNxbrmrsjRyqBgPnuMjHr+NVp9OlNwY1t2diwyuDlce1VImeea3jkkmeRyY9ipjYAe9bwqX0ZpJJ6osNYCSR2t8rGRgseQP/r1gahaR28zpGJGVFU72PUk811z6hEpgt8LHFENuVGSfU/WoBpkbCe/LsIuUUDq7djitDG7TOOETMcYXkhecjr0NUtQ09SEVmKlCS6LxvHoK6CaGRrZ3ZHyZwFYHtjnj9ak1CGECVV3PJE7KWxwykZFTJX0Gzl4YfOCYWRI9oCj7vGe9TauY2jkW3UomzcFAyT2/rRcFrS3juERpI1bayp1zinp/pGlzS3EmZJ1zheCo6AfUVg462JaPO4UabUGiSZJV3b/ADHwoBB5BJ7CtW6hjn16/ghlEsUD7w6jAYcHis+OV7hrm4uEZyiSW4cKAx4xk+v1xXQvaortIoCC6ghmieMggYjwVPoeOaz6jXYgnjItpPs/zCQ7wC3AYHg4qzDeNLFFFdL5ZRWLhT396WOKd1soJdiPL+8WbqJUA42/jxnpULy/c81T5oH7whRgnPU/WmUjQmLi3WSPe32aIbVUYA3Hk/yrptHnlg3KVzvRd28bu2c1x2nzsBcSyg4kbhSegxwK3dM1iKGzKuN8qsPmz0HpV09wkro3ZQjyxM5wgb593HX0quEMWoW6W8gbDsI9/Q8etNuQWtknRFZSem7gn2+lXpIoYYDDOWi1ABZrd2bgr3+tbiKO2/vZ2tJP3kRZmcbScVmySTeYomVUdP3bKvOcdxWrBdwxFZpZpI5cOgZPmfPv6isry5HtpJYsPJG+XV3xvXHpWM0zWMja0meT7JsibZGrhhkgfN/WtLxFcPFp9vKUV7hJNzSqPx5rnNPeKzzJJgecoYIBkIw6Umo3Yu7gyLgxgDkcfXiqU1y6icbyIboW/mpsmKxzESHtk+pHrTZFKzl1ZlQnCsT19aoWc323VFRG2RWqszjghuen4VqzIbcRyEuYnPyuB2Nc6jd3NvUhR2aJGwroTz+PX8ao/apXlKkMRCAuYhvBbt+H61pTxFbdlhPA/eA91P096rWWA0ZEDhic7IzjcaQ7k1vdI8EaKG3liSrpt596mguWC3Cyo+0lVbBwwH92ozc71W4JzKpJKuM8f/Wp86+VLvLCQOFkU47kcgiqIElY204jkYLGAXTcMkr6cdaiCeXLhZEJzuUIedpoidQsguAxQ/dA/gPr9KijMYdpFkUSrwu48PntQM07V40e3aVFYqrEMvUnkciqFlI0XlPIrFF5OBkMM9TUhmhd7h5CySeV5aAcYY4zTreU21tKsbYErc7x90e1F9SJDL9RbT3DJwZXHkqoJxu5zRPGNsASMtMp+fkAH3HvVGZzLfFvvLD8qseQSeuPSrCMqC5klTcDHsiY5+Vic5ponYpnbe3UzOQqxRkAkEHIHHWieWWaTZcHLIYxjocHHJ+lSbAUcOrKONvPBP1qvrP7qCKXLLsYJJt5yp7/AIUmNbFmRF2tcSkhQWVGzww9we1NCukTMGMh+RQRyDnt+AqrcBpJreON/NtznAPJx2496dGzowtWJ8pmLLycZ9PbFLcRb1A/voWjTAkI3KRwzdyD2psU/wBiu/JvfJdGcTId3ccBT2II7H86fNCVmVZCrI3zhQeVGOhrM1GCNyY43CJI6q7jnHPaqIK19HcXCkNlJHlaVX+6N4549u1ZtxcGSIyxqVaZFZj0JyOf1rSvJJAxeI9MqpBwMdM4rFt1RpjFIrbI920dCOuKCTFs7kcLIu5en1FbGlzJZXSQsxSCT7rDJAP+NcxG/lSgjoeMV0VnIJoXty5CN6dz2/WhDO0s5igXlcKD8w447ZpRMzndGSjxnOGHUH+lY9jc7khkJ+eP5JY29hyfoa0rVm3vGxKy4yC3deuBQwNOHoyTquUbOV5yvt6VeWWSWBFcBlClOBjdj7pPvWfFL5TwTB/9YDG6nn5u3HpV1WjSzEcDiTzl3HPG1wenNItIsurxhSSy7o1JLDIDA81ZaKX7fLHA26InEiuenHUGqlpDLPbhkOUjfJHXg9QK0rJlW8IlRXRsKwcfLnHX1zSSsMsQZMZQcbyFAIzg/wD160bYYibzR+/5UMDgH2NYloHa7kgDYEcuQ3QMP5itmCNla48sB1cEnv06n/69USx/mn5FmZs5ycH7uKnDia4RxIoIbCblzj61nPBM8cJ8thEzkrN07ZxmrlrK/nxoyojRDKuqHLntkelSnqJRNlilxcqZXEckfHmeXgMAOp9O1RnYJJHYuqbd24tu2nqOKNOt7W5iubi8neO5tijxRBd3nZbkZ6YxSz7ZjdTRp8hOcPjuehFWTYfDaTXlrKbSKTfbZkmlVsFVPfrWSLaKGKaaNriK7KEROuCDk8k5rRvIXULJulEhi2syLhVHZc/xe+aglaFNO/0pgkyKvkxlSA4/iOexzRfUSb6HOf2c6zvN9qdljXCkpjLd8CmpLJay7fmUgBir88Hsfat3MTKGl+ZMFvTmsp0gC+ZIsWW+bJ+8fpWsHqaxd0Nkk+3MVgUnK5zswOBzxWbPdCV3t4m8ssBuI5qS5uWW6xbFlh2YB9z1pNHtWWbcyh3YngDkAVcpWBJJXKb2T/YXQqMSFiO+c+1YWsbprM78KYlwzAbfm7L9Pauvul/dKx+8OMHjAzXN67bxJLBcSZNrHukbLAAkA4JrOWqIctdTjIVWV9qiMvJKMqCBt9a1rSSMIyPLbrBZAmQLn54wQcNj16cVmaEIrjZe3axjc7HGP7w4NbNzDbx2x0+2tkDufMlcEgOOynsPWsyW3cfq1xdajdR3ExFtlNluFbIhjzwgrOu9hUiPdlsMxZuc98mtOQyQoII9kqBRtbH55/Gs2OMwmSNo/NAydwwc5NBSJrcsrLD5flGRCV8w4AA960YrSOaYq8jgKcKUAB/H1rMlhcabfw7HLKVAdAWVFYgAk/XFaNncC2y00ZVWTyiQOVI7/jQhpu5eskntp5La5kcxIxbA5B+lVriWW4geGCaR3hBMG4+hyU56ZqfTdSEccsMkKyiTgMBllHXrUt8weCG5idPMbG6RRkE+hB9q2Suhp9xbNvtVrE6ZieZS4B6gd/14pbsSRIwVY3ZV6g8PnuPWq+jj7K1/bGUp9mYTQY6bW+8v50s8klxJAMlmDZ2jjK46UpNWGrtj0khM6jLKnlja23JB7jHoD3qC6WeENDBtXzF+ZmGcJnll9ar20wkuZxG/yDIbnoc1ckMbQjzkEj5wnzHgVz3Zoirapb24uikTeWuI45AuQPrW82rQNo6QXozJ0Cqn3fesu2ijV13TPErH5hsyCuOtQ+UzQK2Y2TPL8/L9RVRlyodlsXTEPIj81m8x842gj5T0qKFXtpIJUaMwrKIwwPO7qQR245zUMtwzh4pj80Z+Q5+XHfn+VJBOWRnKhYG+WAY5yT98+p7fSsm7uxVrFt3RpGc7fKmdmaNDgKO9QtK3yI2WidsqS35VLEGFsjHdvYlWwP0qONYQGiupRtZcLg/cYd6sRaSdFspSAwllBDAgEY7YqhGhG2Rx8g4Zeu33p9z5kdrErDdwCzJggA9P0FNKeUzESDceOvBGOhouIkUxlxNG7SOz4YE9PercvlC4YeaxQKCEYdj1wayvNWKRZYY1AL7X3Hgg/wAVSgqyxuWGULYBGQR7ULclpslvpbeWGX7OCgVvl5Pzf/WqGZd9pu8wCEnaSOhP061DM6/aQFjwijI47mm3CBIRtbfEqlmdRgo3oauxm9CxKI4bJcFWVOBzk5I44pjmSOSNHZCm3c6jqPaktljSICXaXZtzOi5xjpitDQbQalqMVnI0WZo5X8xs5+VGYce+BUvYpMw7R2h1CWIcwwuGiZxhmU9sj0qUxxFFilaZOThkPIJ75plk52bT8kL4G3Oc+vParMUbPbu7xrsDsUHqR/nvSWiBjLm4c3O9huMaBBl+mR29TVZzI0TPGVYbj1Gdx7n608F40SSQKUwQpKjLfWqiyzQQR5YiI5cBR931P0qkQytdSMX2qQ8eQu0Dk+wrOScJJfSzo2QOMfMcngZx6VM53uJS5Kh8/MCMn+hqpdyyIt0rOwWUjHy8n8aZJyjNuNaelSAy+WxG7oPesun20nlzK3oaQzurJzMkkbJvYqcknPGMVrWUjvMZGmAaOJcBhnB6Z/KsXTnH2iIvjypY2R93GeODVq1l+VIiQWKgBlH3gPXNDGjoI5UeeJZwwR33ArjjjHNWbd9saqkiuyMWGVwRg45rMtYvMgiBTD4YFskdD/StG4dLdQ8ZygClgwwfekWkbtj5bQbQ7xlpCAx+UBh0J68VdJSREa4RWkyUaRc/MexNYVvO67owuVk+42fl9q1rUM8RjkjdZA2yVWbaAezA9j7UCkrFqR1jiF0IwEVQhPOTnvmrLXKQXwljH3vkYLyucZH4VUgeWOzlkKRzRlCrhjk4PGQO5BFFvKn2WOGSNjJGMZC4LcDBqWKxoWFs0TB58MHDKrI25VPrjtV9khENuiXB84gsdy8BuwDZ+YY+lZMQaMyAcDOVBODg1bDRJLGJT5UbHOZAeuOBkUIRpQ7YkTdKxbb8zoMkGrsSOqxNLELeGUZV7rKq2OduR3NYltJ5S7hCrly0e4fMh46c9DUq3LmFbaSBnYN8rlztUBfu7f6+1XcRb+3iXeXK7DuKQ5O0M3+FRXEKy3CyXMyOrDG8nglR3z+VVkjjkZTLIsQ2bygG4k9gPxpURvs0kfkJIQmFZ8AgZySPegSVia5lS5VmiiCjapIDDnPAxWJqNoYpGS6+V41wVxnPtU91I8RSYcknA249KjhZZZojMzqmcuzDJz6VSkVFWM923KkUaklWAGF696ul/md1XBQZY55AqwyRo8johLDgYwAKz7llRMzIw3E4Knt6Gi92U3zFG7l3ShH3HKbgQRis/UYI9R0J7Uq26VHXft/i7U+SJ5Y1dmxgbR9M1NOdtrhQ3lxZO7d1JGKdyZ6I4KwuBYaFbCeFNyccdSfQ/jW5Ebnyi5l/e3LK/Axsx2APoPWszV4WttZ05xCJYRJvZWPcAnFXr24aX7GC7KpVpAuOnHA/WixDRM0BjhBUHJJ+YcEjNN0+E3eqW9vCyLNLJjJXOUAJOfw5rQglW40oBY2Z5FyrjqMdsVk2d62h6qNSJUfZoZHRtu4lnBXGOnGc0pKwXIPt5Ky2cToIZ182TjrsbgZ7c1K8ivawF1G5CSHH3ucfKfUCqSYjmik+Qr9n2MAMBtxzkiptoyig4BBxjntU30LJpBJDIgIZDnA+arP2iJUiARjKnzMH+6xB9arLIwAZgWZcbkbBBGOtFy0bxiGBWMkgJVpJMZWhSZSdyW3unuvtspClxIPkBAAUDtTbq5a1RpFQklwkUik/e9sdeKpmULZ+dx5pYYiXjI96ksy8lw9zKEJyV8ntFnjj3pO7LReiBCoo2JMRhmzw565PpT3doywmGGXBLY4596q/aUi3B4/QKPSnTPFKzBWYIeDnHNBa3LoLzgpDjf2yMALULy/Z7eR/9Uqtlue59u+aJLpppUaQrGjsIxIq5wR7Ul1IqSM8kgkm3YUvjGPTApNBYgu4pbiRSiSLIrArCcZce+P5VqWbxzJF5+4CHBCBfvjOCB6e+aoxsYU3BNssgwjkdMelW7ARve8koM4fnj64pKN2O/Q6K0vTatIbaPekqlVRwCFXvWfqUYZ1juFjGV3BmTBz7mpFmkDuLGI3Dr1DZC4FLratHDbyStEXlh3siNxGa6JQVrGSldmPuClDGgU425Y8Z7Z/pTN3mB4pSVfPVx3/AMKYH3RossW8SAMpzgHHekI3xeYMyOCcj1T/ABrC1tjTYcXjJjBQK4YKVIxketU3caddMZ/M+yO2WPURN0we+0+oq9LH5fkvIqtEyc7iSVHvTmMMkZiR45IXJY706r02g+lFhNkUkXk3CrMoAf5gVOQwP3cGnNEzSrbqNvmctuYKD9TVa2tDb3pVW8yw8oloZG5T+7sJ/lU9yVRVETne+0eY/OB3A/xppmT1Irp3kdzAo8hcJGVUqQBwTjrz60/Tp5bXUVnhk2DeMO3y8AYIX+VVp5HuMrHkuCOh/hB6g0yedp32Qg7Rnhzn8aBpaF6BMXUkIwkSg7/lAIA6n/PrVeSRZSZEVjE2I4gW+ZVzyT2JI70x52lXzXgUQyJtcEkb26H9QKa7MmnW8akrtbcVPY0WBkVw0Qnkbe7BPkGecjrgVVlJdyU53YwD0x6VJdSZMY2sD989OQKRB9nRpEZWdlBIfPftTRBTmEhUJIgJL4JX/CqtyTdNPGHH7qMzNvPIA4qR3Vo5JGYhgMqoBO4nt7YrGv2byBI7HMuQMdSP8KZJh0UUDrSGdXpJL2vmIP8AVEH149q0YpDlCqEMuSODk1gaGxeIqCNwPQnGa1+TGCARsyTQB09oYjICjS7SueecMRzx9av2s/zHzU3KBsYYzlf61z2lyBWzuG4DJDd8dhWvHISzGNgFZhmMeh54pFxZejEccLlfLdDyNw2kA1sWsrKJC7kyFA2GXhsdVP1GDkVlWMyqJY3hjeOVAH3DO3uGB7Gr0EYZA+H3qd6kHkCgJO5q3EhxA7oAHTKueA3v9e1TF2SBgylQVWQPn5jzjis+GVpwYGDuFO/aDjqeo9TVqKSQyww3O0hSY2BPIHb8aVgRaZDOwWRt6uFUMepx/hSyiWSENIpCwnbtK8sOzAU2LJ+0GN1YxtlxkfMPXHcfSo1u42EiSMkrNGpjKkgw89Mf0osS9zQhuSv7tYkG8YbaTjPZwO2R1FTWc6yXsSmdolhOWboA3v7HpVKOZ105nPzeXISfLUbuR1qa2nSa1Ebog8wh9zKM+n1piLUjiWa3tY42Dsfm3OTk59e/HapXeKNitzFukVdijdkCojKI1MvysVX5ljymxvVh3qk12JH3ThuMBNvIPPWmRe5HKY4owHLB1fhV6Y/HvUYuI0LZjO0/NGAc4+tMvI4pLlSZXCMWYf3vypI2xH5QlLBV3uygZCetS2yiYPsEpJZyW3MR0FUdTSMsTuLYUEDNQPeCK2Ecb7fOYOctx36is9rsrGMuhCsASTU81mNIdqO93Ee/YjgHaKqoULxJtG4Nlj7DsabeyZnEgKyOwDAZyB7VDM7Rl24X5OB/OqTuOSINVCzuSy/KCCOOnvWXpkS3RDwlkurKZlwDnchHpWs77wUAJOzOQP0rBttQls/EFuhaOKKT5VJHR+2frWsWQyeO7S31GW3bzJId3mRtkqAe4yOh5rOv8Ij2kN1IfOZgySsCuByMZ5FaGvyySyglY4HYFiAuMnPNZOnRb76ODeJY34R2TJV+o+nPHeia7FIuGOZAqySqJoQFeMkHIxkfWk89RDyQAzfeHY+lRRSq5R8qjuCHZlyNwOCCfaniGZ5Yyjq+44wq9WA6VmNeZdF5C53SGLzSDwDwT/SqpnExWELk53HjBxUISLyl3csSQSoxgj+tTxjzWSDKtKTtWQqcqfXFBSsOnaBGRCADIwAZj0q1aRO87QW8YeYHO0dTgZPHqAKg+yJJPLbzSrIoUqWlXAJ/xq3pdtdw3sCytFdg/Isol2FAVIyT6+vqKCrlO5uQkMbhFaSR1CEirMDKiSgKWLfLkDoKht95uBPJIzJExWM4+UnoTirc0yyqqzoGDKMOPlOfWlcsn06aO3E1tqEJkgnU4OOjdj7VDdwrc3SwlY7cKAIyfQD7xpDNC+yOXJVTtcnjJ9jTVZTbEyuBOkpVeOqnsTTuK+pHFl4FRSCU4BzU1zcyxFZVEj+UAh47fWomR0vLaBm8ku+0rIMhQBk/hU8UTRSylZlbnO0A4YD29KFe9wuSNqs32WQQXUkMUmDIqDOTVN55JV/eHcpO0NnP51Zmt7OaVnkg+zSAZYrwAPXFMW1EQVSUZhHuAB28HoabbKTitiSFfNi8gSspzhQTlRRGXaTe5bCjDYXgYoiRkBfByQVP+NOSSOP95cO+G+WRVPP1A7io1E2AmdXDf8s24xn9KcuWuBDExaJx8vOee4qCW4aSJ1LglD8q1CjzQxCbakcn3YcnrkcnFVcl6mmWijiSR59uTgbDlhjjBFZju0mA2XVidh24JqpJAG3ySsxKjLZYfe9qS3QSRkK8sT4JVeoz65pmfLqW02iGGMxc7icg8nPb8KdaqVbDqcqedo+8ff2pbgIIRLEWAHy8tkg4/wAatw28sWj3E8QV5pytnEit/FnLMR6YwKRTlYqWUoV7hntSIZsnauce49uoNVJfMlYFEII4Bbkcdqs+RKmLcSsWQMzAnp61Rurho7YSyfKP4Rn+L/69AEMQldGuJmViX2tvPvwB7VYvXlfMm1F3jg5J4HH4VFAfLtY4gjxPgSbj1PqKsTFRo15cMFIVcAEcHPv9aaM2Y1/IbaJ0KnAT04XPeoG2ieIBVwA7njsqHikAL27I7kyyrtJ9j0rPv7uUO6vnzBF5P055piMiiiikMv6PL5d2M42kcj/CuhUlSsgO4EYJB6VyULmOVWU4INdNG+V3AAhh0ximBo2pXcxVl2tjhuw9a3LP5gGVxhRu/DODXNLCGACZDNxgHjPsa2LW6N3N5kgRGKhGG3A3AYP4n1qWNM6KORhEkiZSSN8Btv3ecjJ7iteCQSRu8TFbhDuAYn/Vse341gRSloFOE3bhG0chOVHY/SrkE+Y7VypDpuifaeQpPH1pXA3JMI5SWBtvAPPb1FBQTT7WuPLB5j3nIPouR3PSoWbMCHdlC23cwxxjitCNgsO9ypgJEbswyVTqG45yPX601qNOxF5cCXCMrfZ1ySruc7e/NNNwBK8iFmkf5mGBtf3FSuivePE9yibYyyyFMh0xgcfWstbaR/M3RsAndTtO4Y5x2yKTuCt1NVW4O0Avxgc5x/Q1a0+4nmumkZEuJYXRikg3E47YHUYpkAsUuWW2a6VDgEyuCQxGQc9CKFgFo/2mWXy4jKFAQ/vRkdvbNVYTsW7i8g8uWQh4pGO5UCE7iD93FMSMx3ZMg3rIqsAuBtPX88dqFaR54lkYS+eSyNIQDjsSaoCYRzyMVAkxyccAj096GTYsPPD+8aFS80Zym4D7vQis28EcqtgrCZWClVOPlNWZ9RSC4inNsDMUKyFhgMT0OKw5ZzPcvGDwUZg2Mc9qmQ0rjJPvosWCoJVlUdMdz7UyW3AsVaPcoLLnkHNOjXiZi0ZGwBSSflHTj6k0sk0dtavGNu4OcsevTtSSKfkUZmLQsB9yMhV56H1xUFzIVAUY6c96ezyLDL5hJMvQYAwD/wDWqszCNyHYYVQcAc5HTP8AOqsJvuSRTKLOaTO1+VAIPOK5/Uwk0jI+TA67jjGQw6EehrcmDgQIQVb7zZbjnuaw71xHdlPkkTacjPUZxkGmQ2iS0nZ/s8hzlk2b5GHzHvn3qrcxRljtOxCwYFv4W9u+RUdscRzwbC6FVfbj7u0/eHvVyBvNgO8IY93mIoBDcjk5NA0Qs80UrpN853Zk2uHBbruB7g1O6iKJpkYKow+d3HXsfWqkkQYLJyYm3CMqNrADpuB4NQBkmu5CxV0gIQRBeBx1pFGrNtjiMm6WTzv3hJI+Q+n0qeKJYh8qku65Hz/yqlKkjjbCGb5SSqDovXmpYd8bJNFLEyqAygc4HTHsaEBd8iJ4YVAO+bkqeob61ctNP3WrebLKJoZFkjHGMjrnPam2RaSFXL7EJwJguQj45BFNa5Yu7FsNtxuPGa0UBplq6WKYmSGMfZ5WLhFGzZk9Md6pTxzMIQFPk7ipYnp+H9KuRRtt+1xyqkbYUxhS2T7jtVK6n+zyAXSyorNkNtyp9we1Q4pGvMiOSKZYNrowiAyrDkfWmAEorlMw52uRyDntmpJLsJtWObawBAAPY9evY0amy2weK2RTIqKVwCOG6nHtSHcjiminv5WKeZbwIYoZRw+Tznn8qJmdCCA4UqMPnj3qtZwNBAkauC/U9AQc96uMJI+CoiBwSrcg0CS1uRG8eQbpOVC7QS3BA7Gpp7lrmSQO+3jCDbxj+7/9eoLi4VpVZlVMnOUGVzUVzMZn64QHcMDofWlcZoRXQeJIwcOpLDngr6VCLosMog2rkhZBxUMascvIw2x4wfUUxJVk37GyxJwQetFwHxqzlJQoK5yQP4TVhmmkyrwiWdR+7c8ZUnOP/r0xCI2DR7ivRwe+eoqWMwmEcbQCTyf0oYmiCV0kTy2B3gbcvgFTTiDDGHZ1KN8vB5H4UsVvI1uzEKzSIQSDl1wepqMMDJkgiRAO1NEEuEkNtGjKY5X2np1HqKs6jcqHCWxItYgQgIIOfXHY1WKxL5aTxnazZkKnBx6ikZsk7XUKQWUscYoAbKNkZMILHgOT2Lc4+lVZ1Mxgnx/o1vlnZsYZx0AHpTLgyXE0KhwsTY3FeTUbyKEWIJujjPBJ/pQDZI92ftHmSqGO0/IRxz6Vmzy+cskLtLJaRIMqo4L5GKndVMZMn+rKkhicZNV53aFNkeWadhtHTp3pmbYNKEyTnCsCRt79cViXh+0XBC72ld85PpWpqEypGkQY+Zu3FSP61iz3BUusYALcFs849KCUVKKKKCgFb+jyEwDccgcEAdKwKuaZKI58OSFfjj1oA6cfdXy0Ybx0ByCfUVPayk27NGo2clhj5ge/61RjkLKf3jKR91/7tOilaGYOXC7/AJZATxn3PvQwOqsLiGYKskhBkXGVHRuxPpV794hijlJy6BRj17VztiTtZiFwGxKitkr6H1/GtpW+0JHGobzWGVZemRz+eAaQ0X1lkV3jMhERALIDxuHerdhceW4Z3ZAAQccAqeefx5qhbNB+7kdWI+62R6+tW2iSOGcQ52Rtgow5wejA9xQWaM00ZgiSIODEdw+bOM88ex61aku3mZFU5YjbtPH0JrGhYTvEAFQp8gJbH0HtWjHIqsqzRsCrYYryRQQ0SSrLFL5MoERiBBB6kjnmlhN7KbcziERjIVgT36Zp811csHl/ikBj8yRQwKng/jVKyuEmg8qS8m81WOyMLwce9MVjQnSa0n8udo4pEXIXgqAemD3FUVmO3NzIodMhsHO71qB5JLkSjfCzvgLGQOfTrUUx+zTvH5URlIJJBOWz19utTe7C1y7dXm87Vi3mQqw3qSwwOMe1VYpGSWQylXkKApk8jJ6g9CfaoRdOkrjcCSoXcDn8jVeWVlt2Z5Bw+1Y+jZPXimNLoWLmcx2yCRC0ajBGQM/NkfrWT52+6dW2s+dxAPA+tL88pnYsWUEKhY8Ht+lQRfu/N2ISwwWJHL/59KTG1YgIMt7lFYn5c84xiiQ+fKwDDaXDAkHjHYYqu86m8Mcb7Qn3iw79Kk+2CAqyLu8gNtxxnHGaESxt3cqI88GQ569SorAsJDLeag54QII1+XJB6gAfXrU948sNmJ5QAig4Oc8ntVXQ0jjsWkmZzJJkgY6E9DmqEWGYs6yqn+qAYEnGSeCPz61oyztP9ncsqNsKudmORzn6Y4rOkJRiWRpDjII5ycc8VY0t1mtcuWlcvkB/4R6/hQAtzcEOQm1MqBjn5T2z/hVSW2+zlJfmJb907IPlfjPapzkXEmWZ2B3rjjn1pJnKiNAxXcQ4VW60hk9oonnaJX8qVV6Z6/8A16Ig0Usu9lIxzhfvU4MzlpJIkEJYo+0jJ9j3465pTjy0hIZ+eGD9s5z+lMEy9YIRGV8iRX3bz8+0AH2qYRwxRLG8hdSuT2KnP6io5Zlnu5pLiVFnBDCPdj5DVg26iFHWVGXBySeg+tbRFcbvltI5dshIkIII6ED19DTb25aTeqtiMHJUtnJxyarbpoUYRsrD0B4I9apXFwbhkVihVRtLAYwPepkaR7heSrKELqHUDCnuB7VEkEokZwwL7crk5GD2HoasNFasFJjKSYOxwePpinESRQlTCdy4ycZNYo05iWJxdxSkkrcRrmQleoHemRNIET5tyzLhABn86qXLmGUXcLqyRkIygduuPep0AiZmG7qGRcetIQK+1ZkIITqcnBBHHFSW8QmeMGTyyxw2RkYqJ0beXbDKG+bA4555qxG6ffwDGDhsdVOP5UFEqN5FxlgGiJKZI4PpToGjR0V4UMcfXjBOeozVeORlO1ORwfm5FWpZd6y/LyeDtX+VADWhX5/JmwuPlVh09s1NZwmAGS6iDCRSixMwG5uox/jVSN1iBuLiLz1VgAg4w/Yn1HtUUs0s0xnuJC8+ec8BQP7vpS1ZDZLL5uS8o8t+MiM/Lj0zTN3moyIp2secdgKbLO7b2jXCkdB1FIN0SJuLJJyGCnIFWmKxLLctJhCy5Hy9Ow6VAjYdvMiG9B0z1oaSNYAZFDqORng/nVQSLI4+ZQx+X73f1pdSiUyxvFJK64nIURbW2gc8k+tRzzGZusaJGRgL3HrS5I6GP930Jqjc3G8EzqpVvbg0zOW4jSmRg7MfLU8Lt4J96jgJkme7kzuXheO57j2p2VHLrtMn3UHQL61HcFzCF2svOxcDHvnNNEle5lXy3dmcDhCpGSxPUisVutamqvbvbRm3UqwlZRjOCABz9c1kmgSCikzS0DCgHByOtFFAG1Y3B8rcOCOvc1qK6M53t97G444YduK5m0m8uQFun8q20ffGFB+Qfd3dqBGjbztGWVsb8bcL0cVtxziENG6LIpUNC6ZKn1xjoRXNRTOki5+bB6HuMVt6bMQY3VmyDj5WwQD/AEpDNi1ldQGRi0bfKc9AO9bUbea+2P5kCGIp32dciuet2UedEsxhUSFQJFzj3OO1aVpcTW858tjG4GQw6Ef4UDLkEUIuI1Mg8psg72wAfr71eWeC2nIQYnQZKlshhjj+dUA0UxYMgijkzjacqpxz+dNLLGkHlqm0Aq7t3A9+tA99C/HdLGjS7fl28oTnH0qOEJP5bEzIAxztUcDt9OvSqvkKqSeZNGWUnYY3zz9fTmnxlnkVisjllG7fKCCaS8wJiIPOb7TGSEXKFM7cjpknpVRdk90zxAKC2FVOWJ9PpTiWW3kQQP5ZYBmz39Oaryzw2/zbS6Dnbuww/LpTEPBHntKU8kJ8+N2MHp+NU2cbJJGLyTPyATzUO5ZmViVcFssSeFHYUv2qKNi7gq+OGHOB9KAHSOsMCxoibyclxnj2qk03l7fs6hpWY5Unpz1NSRXDSuxRXVYyCSOMfiev0qF4gwlkeVABjaCOSepAoEMl2o7SPsZXOFQEZZs9KqSt5byLL92PavB4A/uj/wCvUw5UzttHlAYB9uMY/Ws+8kQW5VioPLyMe5+vegDI1uYyYhTrI3IB7DpW5bxPFaJDJCjRRgSIUPWuc0iJtR1fncF2s5wMkKO9dZEFhiGPOZIWDJuUYcEdPpTAglTbOTb5G471k3YKnuKh0+yNxLdySyhViTeGDdXPCqB9eav6bbteSy25MaNsd1OOmO2KzZiqny7pnjAOcqR8rdv1oERljwsjgSLkNheSRTovmO1sMwyQ23pmp4YIZpJd+r2USkDd9o3IWbHUYGPWoVdVkWFbiCVskq0LEqO3XFA9A48spJgqcB/l5z61G03yiPYoduCR12ikRJ5bhUaWOAE8Ntz+GajFuUty0fJBPQ4K+uR6UrhaxoARgANHvV0KoS2Cvoc+1CTNDIouomcKcM8QyWXt7VXt3eTEkTJIwRiY3XIIx1HvUkVw4jwijaw4deOPXFWpWAmvb4SowsYvLQtgGRssfwqFCglf7rADAz6+9QPLK97Ep8vMR3ZHJx2NWgqSMWuIjklgHTg7ux9Km9yloTW8gXYXA2qCCpPQmr8/lxwRShgJFyWIOcg9qyfJWSCRklIl3LkMOSPWgwXHkhid0SgZKNn86adhsc3kfZWjEQEbA856Z7inQu11LaQMxMu8RjJwCFHGahELSbsYCKMMSc/hS2TbrgtIoaTb5akcBT6/lWdikXgQlwFjQ7DwS3QsByKZIVjO0KPMbgDPBJ6ZqxcQmKNBEzFlbLRn7ufUGqkssnnyyzbBKDuUOuQ30+lPlsO9yUuAjLAzF1ADgdiOox3qFJpXYKgJGd2AcZx7VEJQriQcPnnHvTpJo1iYqqg7gOD3pgWgYGSUOrh+SMNxmoDO20pwVIAB/unvVVrjcWPY+/amKfNJIIEY6DOCaBMvKXaN945Qbk2HG4joaikMkzeZhhkA5PQ01S0aEsHUAZU9aPNkxudSYscZBz+B7UEj5oWjCLIypuXeoLZyM8mmNKqqUCIIwOCOp+tRzFGPyxhQBgbySR/+uopp14DgCLGBjop9KSBvQbcMUjLAAkjBUck//XqDbtVRKzADorfw+pPvTZS2cuPm9F9aEkMUkYm3OerE+lUQx/mbkYknaeA23otVLqdSjPAzLEi43FcZqW9upXPlgFIVOdo+nQVXuto+aWUYQByp6seygUCK14AiwQMeI49zD/abn+WKocHJFS3cz3EjySHLucsf6VCOvFAxMUUpBFBoASiiigArU0yfJ2nnHasunRuUcFTigDoWj3jCht4O5SP6VPZ3ThHikLbSc7c4ZT6//WqvYSedEgzgnoc8g+lPuLds712iUdBnrTA3o7jz8TTYdcBH2naTjoa1IxJFFC292VlIRmycEH7p/DBrjrC4XeGB2sAQ2Dyp9639NuZIikLzu0bkMyk7UPB5PoamwG8sksyr5TNG7feQAYJ7YzUqhmDeZ5ysoyUQDB+o/wAKy0kjEjjf5bAfIAM5P19KlaSZisTTbJTyMdAPZqYzTigjkVXE2WkIXyymAvoc/WluzcspTy5ZFhGMqR8o9jVC2LzmQbwxHB+fGT9KnidhEw8zKLwVVuPoaVhtjUUhVWRWx2DOSxPr7VFMrNGysoVBkKuOtE0/78yF1GeQASOfSopp1WORmYF920bWB+tAiG+YJIVhVwoQBdwx/Kn26J5LblUOeeSeFFQi5jKDaSzcgKx5z64qBDEsZ84NvxzubGTTFclbYJGZmYKPmb5sgn6VC84JAMOB/ez+oqHeixfvVy3UqBkUy4lU4IXavByR2pANv5FcRrAhjUAjJ6muZ1q5DzNFE5ZAec85rR1K9WGAuC29/lQHsO5rBtY2mmGScZ5NAHR+GTFZadeTkmS7uNsMaBeFQ/eJNXLWUNvV1GSuFCPyD7iq9ssMMcQaHdKCcE5JxU5JkRWWMKVbkL15pgaGnyLFdRiQribMQm3H5SR+nNVr1WlZku4VgZG8p+Bgle+fX+tRyo0MJaMTeRIcNnnJz+mK1WuWuUZJbJdQ2hY/MiIjmAA7g8NxikO2pzMiW0bO20+TnHzDp7+1STWq2yKqmJl+8jqc7gfetB3smiWRJbmKQqVaOe2wHPHAK8Z61VspJGhe0eBppzzGYQGOfTHbimIqYkYMEPAHf/CprifNo8scRRkXDSK3DZ45FRS3EYZjD5ikkFFmXBI7g496jEsdzFMmzYqAO2fr0pDZLahYym0OhVQeD19cU6S4APmOXVYjsTIAL5/pUckgjwiKWJHI9KrRLvky7hsN0P8AIUwRasxtIknQGV/nYHgEenHariO0AVesR+fYehqvsRFOCrdQcdvQ0gmlkQhT5cJGGzzuHqKQE63ioJjGsY8zCup5KjPBB7VIw3FmdXjXIITOQ4/z/OmTzImE2Q7XXC4xkj61HAJ7dkgt08+PJK28h4zjqDQAsrgMvlps8w/KmMYpF3QHepUPH98N1Oe9QNeWT7jNaXiTPjGyUOgPfGe3WlWeCfK20d0XHdwBtoHctvqM8wVRsK9QyHOR6UiSqJVDuyA/xIM4qltlR2G0rE/LE8YapRHIWGWTaP4CelG407EjPhsvGQQM7v71R7g0fmAfMDnHrSu+zeybenKseKSFd2GwFRBkjP3j7UDJXjYQ7WVMPhy3ce1PAyy4VeOVwKR54lAjjRy5xknpUcpjEeVDNNuyeOB6YoFclRnU8b89weg9qmkMy2wk3M0bNtxu4FUXYuwMrgHqGPT6VG/7yUPxjqq7qYmxykPO6SMY42y33sk+wpvmAIcHOPUdaZO5f90kYJOMgDnFQysIvl2hrjouD9z/AOvSEK0hYqir+8P3nY4x+FMRpQNykfL/ABHsTU8jXUsa3U+1YYo/LikYAbgOw/vH3NVWkL+RaRMcM4ZiB0piGrKIoXfcWAzye5/xrJd9x6EAnOM1c1O43OLZFCxwFlAA6nPWqGaAJkkMsfk7QRncvsajHBpImKOGH8JzU0y4mPoTkfSgCI5ppzmnU31pgFFFFIAooooAsWly0EmcAqeoNdDbTrMh2sqt1Ckdfoa5arNpcmB/myV/lTuBuX1uWi+0xHbOuAVA++Peltb55ipyCxHzJjPHpSWd55oAwWYdOetRXti0bG6tnZZl5Me04/A0AbFtOqBSfmjK7gVP6VoxzIgBiZTGedr8j8K5O1vlfhywbqVPQGr8UmZQFI3Y4O7ilYDo1kLfO0ccbYz8jbsCntKkkiiKcYRc78bT+VYdvMyqpff6EKQA30p4uYsFoy6jnPAY5z0GKY7mpIQVVQyMw53E9T7mqdwVDYDiNsZJY9T7CopLt2hVU+6DuIx1PvVcguN5BzjLEmlYVy9GzITicbyOCnP60klwZFbYjKu3bmQbj7kAdahE6RQiLywTjJwetKspVR5KkzMNmO2c5BBo2C5LKwjdjOwXYAeBnJI4rMuLwwvv5DKOMDNJeXoXPlsQFXDOzcu56/Wucu7gyMdoCKBjAOaQDbqVpZiWPHQZ9K1tCtizq42l+iq/3TWRaxtLMFBzXV2kMa2xVnYbORgZ5p2BlqJZYTvZ0SQcBFXrnuPpRCVhbMiNMB1UNj60kKFpEVJFG87VMh249ie31qe4hNpO4vrdUuFP7xFfKv7hh/SgCCWVFRYlYm3dxIEAJK89Kt+YktxJKiS2pZSyjGSSaqISAFjlHlE7sL1H1zTtzFX+dmZRgHPSkMZcWx5icsGf5omzx71RkGHVkmdJEIdWj9R0P1zWs0QvJCQzeZGgZACNvA54rMlknxsuIH2r0KYYc9waAIpriRpZZ5YlVmOXx8o3HuBTJ/8ARomt3bc7upBXn5ByacqNNMFkfKrwd/BHtSIssoeSJzEluCVZj94dwPWgRCFQABC23OWIbrQCC2CRg+g5BoaIiJZEw2Pm3r79qYZCCqsSFY84HSmBO5DkKGAjHQ9/xpSxZQvX5f4aj2o0bGLdsBIXdSxBcnzGMeVzj1oAaoeL5nK4Veg61JDcs11DtbY/Y49QetROBs3F2VW4Ax1/HtRcSJDBKrsfMwpUo2QcUWAs288yR+WFjCodxDLxkdxTiTncSqpnkpwT61VSZZSmCQr8Fn+6M06WVsCNyjNztKHPHvRYCeMLkYkYxEk5zz+NMacZBXEjt1XvVWMyzExgMoX+PHU+lWkWO3B2qu8jBJzmlYYfZ9zYEqEAZZemafG5CDeQxIIVQ3IqIPxjBzjjA6UxpWLKeFx045p2AupJJMG3ssQUDg96iSWUcICdwJ3AdqgluGIKpuPdtwwKh3yTEKpGP4UDdDRYVyw90ciMtuA6jPT6097lSDHFCME5Yfe47VEhMISPcGOOAvP5mns8p0+4mgAIjkSORB1O4HB47UwuMnuUjBLFo5m42KmeO3Sqakyu3IRMfM7d6ZCpkZjIWCqcMQOSfQU95o3cwGR4IFPJRN3PpSAbLPvC7NzBcrEvp6n2FNtyodXYgpG2+RyeDj+EU8z2EDYhSeYdWL4TJ9OO1Z887yqqZ2xr91F6CgBly4kneTGNzFiB2zUdFFAAvWrt0hRbZj/FED+pqkOtWZJnmEYkPEa7FwMYFAEBpKU0h6UwG0tIKWkAUUUUAFFFFAEkMrRnIJx6ZrWs9UzHsmUsQODuNYtFAHQT2S3e6a1kjSUc7RxkYqkl49vmG5hDDOSQcH86pQXDwnKmrH2tJcCWMY9R1oA0FuoJVUxu6MDnBNTBpkQOqkj1JAA+orHeCF2HkSDJHIbjmoiZIWIJz685FFwN0S5L7nVWB3YzipYrlFXJ3ncCDt4/z0rn/tj4I2pz7U03BPBVSPemB0El8CMgknvtIwPqapS36hwQ2Xz17D6VmFzIp3MqqP4QOtNaTA2oigdM45oAlnuJJXJLDHTpVYAlulKalgQtIAMZJ4pAX9MgKupJAOetb8ZJIwNxwfyqpZpsjUlQSvBp8MjBZVIysTZyRjGaAJ47gmMqqggjgnv9ae7ss4KSsQCMbj/SqocENl15GQQKWGRgrKwY7iCfUigZcEy+YCYkyucsOOtPtlf7VHHGUyw3DIwOPXNVyQ+fLZsZxsxyPSgt5ZwxVyeCMnNIaVzRuYpbeaOZliMuSwMbAj6YHeqRmmdjtJR4yWKAcNnrTUaFsgAs24AEHAWmkR+ePMdAwyAxJoEJcC4kVsNtwMPlclh61AbcSGNIYyhUYGXwp96kju5oTGDIrFflB3Hp71FcLczhow+Y3OSMY3Y9DQBWjkRXkXfuKHkIfvfSoZmiZXdD8p4wwxt9qneAeUfKPktG2APT3quyyEnzDGNw5yuc0xE1hHFKUXe3yg8da01tvNJIkUAcjjn8qwLqORX821Vo+hMajj6io01WdVwcMfX1NAGzqVp9nn2pKNjjf8y/0rNFqJEXy1zISd2TkY9ajvZ5LucNGNkTICAWzj1+tRSNJFGIFTy1PJb+IigCWRlUeUjyvMvygEZXFORVQneUyRnceQtV0cxr+7OCD1B5oRzCpPPmMeSRmmBdjmT5VMjRwAdU/iNSRQ+aHd5SqgZH+fWqLmVHKyoqyemelQl5VXf5oG7oc0AaE7puAi3gnAxnLGmBl8xWffK3VlLAEVnRmRjlWdpO2Kcw8rlsbz15yaSC5dMoXk9+2c5odwq5lBjJ52rgcVRScowZSqsOhxnH0pjPuYsfmJ5LNTAtT3HmO+391ER0HP61NZkEXMMRZRNFxu4JZTmq0Nu8rpho1RztUyHGfenXLR25ljQ5kxtJDZ578+lAiU3Swqsdup84DaGbovuPf3qvcyxoix25YjHzM3du9VQ205wOaIwCTnpgmkMaetFHYUUAFJS0UAKtSZyBUQp4PHFMBCaQ8ilIpKAEopMUtABRRRSAKKKKACiiigAo7UUUAJSkn1oooASg0tFAAD604c5ptKKAF+vFbxtY4Bprlt/m2/mNjHB3GsSPO5dozg96uwfM5ymwk8AUCuaSyz7CsUpUD0xmnq/nOziXbO2M5+6QPWqqSOHWKJczE4HHNSx2m5XZpP3pPzYGMUwLpibynaaGQhuCUXKihYDGiSvI0KNwMnDH8Kpo0sMuUmcgDHUinIczK8g3SY6sc8Uhmp9peRBHgbQOTt+ZvrUSKssRbMqkHgBeoqIsN208HrvGe9IbhhjJGF6e9A7lhpTOIgSpkA2ZAx+fvUcrIiyI0LebkYbd8oNNnkSZVJt41eQ5DoxB/KmkBdiKzbeSwPOD60gJZWikZmQyAAjClQc/U0shCRKodGjBzxximQmEw4YSHAzvDd/pTWWSMgFCu5c/OO1ABhH3FejNwQ3IqOUy4WMMrgZAx94j396RgqMGimAyMn5cimb3BJ2RFj32kUAQbVDna5Y/y9qhmt0ZsmMFu5Axn8KuN84+ZAGJHK8AVFI8gnYMok5xuzgEUCZTCRiPYQvHAJqu6AtmQ5xwMd6syRqJDkce/SnMiADZgKR1zTEZrbVC+WxLd+KWJ2LglwCvI3d6uSKrABdgG7GR/OqssO0jBzntQBd1GOCPUHcviBgsgEZ5IYdAfbpVa4vfNliMUUcKxLtUKo59z6mq8z52jJ+VQvNRryQPWgZae4klkA8w49emPyqsXIGMnmrF5EqzFEBV14Zf61HHayyZ2oTgFjyBxQBFtB5LYqRSiEEHe2e44qIjA9qAeKAL8iOVaWa4jAx8qqckj0A7VFcTrKkeyBYUjGOOdx9SfWoY4zI2FH19h60SPxsUkqKAEmiaNsP97GcU1SATn0oZix5pKACiiigAooooAAOKUHAoFBFADjSGn4phFMQnWkpTwOKSgAooopDCiiigAooooAKKKKACiiigAooooAKM0UUAGcVZSXK4x82euarVb025W2uN0sayRMCkisOoP9aALUUfkyGTcPNGCMHNTQzRnIZgr9cZ603XdO/s543t51urOVQ8c0fQZ/hPoR6VQhmCbSQcg9aAN1EaVCUKjby249vWnSKba4SOTy2YckhvlYe1ZaXKyKZPPCyL0DA81esLuKe2/s+6YLCctDMw5ibuuf7p9PXmmImLxr5qg45BAZqM7izQxlI0wGOd3NVFeSRcGRUKfISerLTy/lqViyVA+9jrQBZkYKRsRvLIAxxkf41IkkJTcJhvXsF+Y1SWTeSG+Zu2e1PEkYXzGB8wHhT3pDL93IsYEJZGI+ZSp65HeqhYMjMxwB1O7NRNKskpfG0H36+9RTMD83btg5osBLk9W2+3NC7icZGT6UohVUSW8mFtG3K/Luc/RaLi4V2aO3WQquSskigEigLgI3CliQQc9TjiomlYBVGNoHHvVd5cON7EnHTFRtOz4ztDE8D0FAFl9rMXxg9MZqJzubIVVIHYYzUXzMu8ttPf3qFp2bMeB9TTEWzmNPmI3HtVF5eW2ncT09hTJZWbrUeT1zSAD82eaWJCzcY455qxb26NHJJLIqogGR3OfSmSyoF/cqVB4OaAIpnLys7YLE803ccDmmiloGBJPWlVQepwBSUUASGTAKx5CHr71HRRQAUUUUAFFFFABRRQAcUALRShTSEelMCSmmiigQhpp6UUUAIKWiihjCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABQOtFFAG5oXz6fdI/zJtJ2nkZ+lYp60UUAKvUVMeoHaiimHQcpOzqaWF3Mqgs2PrRRQIsSk5H1qZecZ55oooBDbflTnng1oQgCNyAAQvUUUUAYyOz3sjMxZt3UnJrQB+/8A7tFFAFb/AJeFquB+9uPYH+dFFICKT7p+lNl/49l+tFFMbIKVaKKBEjf8e6/71Q0UUhi0UUUAFFFFABRRRQAUUUUAFFFFABUkVFFAmSGoT3oopgj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous annular plaques and papules are present on the penis and scrotum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Kosman Sadek Zikry, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Annular lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A violaceous annular plaque is present on the penile shaft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7833=[""].join("\n");
var outline_f7_41_7833=null;
var title_f7_41_7834="Irinotecan: Drug information";
var content_f7_41_7834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Irinotecan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/44/1733?source=see_link\">",
"    see \"Irinotecan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/48/15113?source=see_link\">",
"    see \"Irinotecan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Camptosar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Camptosar&reg;;",
"     </li>",
"     <li>",
"      Irinotecan Hydrochloride Trihydrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Camptothecin;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Topoisomerase I Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     A reduction in the starting dose by one dose level should be considered for prior pelvic/abdominal radiotherapy, performance status of 2, or known homozygosity for UGT1A1*28 allele. Consider premedication of atropine 0.25-1 mg I.V. or SubQ in patients with cholinergic symptoms (eg, increased salivation, rhinitis, miosis, diaphoresis, abdominal cramping) or early onset diarrhea. Details concerning dosage in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, metastatic (single-agent therapy):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Weekly regimen: 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes on days 1, 8, 15, and 22 of a 6-week treatment cycle (may adjust upward to 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     if tolerated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose level -1: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose level -2: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Further adjust to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (in decrements of 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Once-every-3-week regimen: 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes, once every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose level -1: 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose level -2: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Further adjust to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (in decrements of 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, metastatic (in combination with fluorouracil and leucovorin):",
"     </b>",
"     I.V.:  Six-week (42-day) cycle:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Regimen 1: 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes on days 1, 8, 15, and 22; to be given in combination with bolus leucovorin and fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose level -1: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose level -2: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Further adjust if needed in decrements of ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Regimen 2: 180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes on days 1, 15, and 29; to be given in combination with infusional leucovorin and bolus/infusion fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose level -1: 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjusted dose level -2: 120 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Further adjust if needed in decrements of ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, metastatic (unlabeled dosing):",
"     </b>",
"     I.V.:  FOLFOXIRI regimen: 165 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 1 hour once every 2 weeks (Falcone, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical cancer, recurrent or metastatic (unlabeled use):",
"     </b>",
"     I.V.: 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes once weekly for 4 consecutive weeks followed by a 2-week rest during each 6 week treatment cycle (Verschraegen, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CNS tumor, recurrent glioblastoma (unlabeled use):",
"     </b>",
"     I.V.: 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     over 90 minutes once every 2 weeks (in combination with bevacizumab).",
"     <b>",
"      NOTE:",
"     </b>",
"     in patients taking concurrent antiepileptic enzyme-inducing medications irinotecan dose was increased to 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (Friedman, 2009; Vredenburgh, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Esophageal cancer, metastatic or locally advanced (unlabeled use):",
"     </b>",
"     I.V.: 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 90 minutes days 1, 8, 15, and 22 of a 6-week treatment cycle (in combination with cisplatin) (Ajani, 2002; Ilson, 1999)",
"     <b>",
"      or",
"     </b>",
"     80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for 6 weeks of a 7-week treatment cycle (in combination with leucovorin and fluorouracil) (Dank, 2008)",
"     <b>",
"      or",
"     </b>",
"     250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 3 weeks (in combination with capecitabine) (Leary, 2009; Moehler, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma, recurrent or progressive (unlabeled use):",
"     </b>",
"     I.V.: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose days 1-5 and days 8-12 every 3 weeks (in combination with temozolomide) (Casey, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric cancer, metastatic or locally advanced (unlabeled use):",
"     </b>",
"     I.V.: 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 90 minutes days 1, 8, 15, and 22 of a 6-week treatment cycle (in combination with cisplatin) (Ajani, 2002)",
"     <b>",
"      or",
"     </b>",
"     180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 90 minutes every 2 weeks (in combination with leucovorin and fluorouracil) (Bouche, 2004)",
"     <b>",
"      or",
"     </b>",
"     80 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for 6 weeks of a 7-week treatment cycle (in combination with leucovorin and fluorouracil) (Dank, 2008)",
"     <b>",
"      or",
"     </b>",
"     250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 3 weeks (in combination with capecitabine) (Moehler, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer, advanced (unlabeled use):",
"     </b>",
"     I.V.: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, and 15 every 4 weeks (in combination with cisplatin) (Ohe, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pancreatic cancer, advanced (unlabeled use):",
"     </b>",
"     I.V.: FOLFIRINOX regimen: 180 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose over 90 minutes every 2 weeks (Conroy, 2005; Conroy, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer, extensive stage (unlabeled use):",
"     </b>",
"     I.V.: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, and 15 every 4 weeks (in combination with cisplatin) (Noda, 2002)",
"     <b>",
"      or",
"     </b>",
"     65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 8 every 3 weeks (in combination with cisplatin) (Hanna, 2006)",
"     <b>",
"      or",
"     </b>",
"     175 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     day 1 every 3 weeks (in combination with carboplatin) (Hermes, 2008)",
"     <b>",
"      or",
"     </b>",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8 and 15 every 4 weeks (in combination with carboplatin) (Schmittel, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10819706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/48/15113?source=see_link\">",
"      see \"Irinotecan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See",
"     <b>",
"      \"Note\"",
"     </b>",
"     in adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Ewing&rsquo;s sarcoma, recurrent or progressive (unlabeled use):",
"     </b>",
"     I.V.: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Weekly dosing schedule: No dosing adjustment is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Every 3-week dosing colorectal cancer schedule: Recommended initial dose is 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose for patients &ge;70 years",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5519575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dialysis: Use in patients with dialysis is not recommended by the manufacturer; however, literature suggests reducing weekly dose from 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and administer after hemodialysis or on nondialysis days (Janus, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F184462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s recommendations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liver metastases with normal hepatic function: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin &gt;ULN to &le;2 mg/dL: Consider reducing initial dose by one dose level",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin &gt;2 mg/dL: Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Alternate recommendations:",
"     </i>",
"     The following adjustments have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin 1.5-3 mg/dL: Administer 75% of dose (Floyd, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bilirubin 1.51 to 3 times ULN: Reduce dose from 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Raymond, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F184494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that new courses begin only after the granulocyte count recovers to &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , the platelet counts recover to &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and treatment-related diarrhea has fully resolved. Depending on the patient's ability to tolerate therapy, doses should be adjusted in increments of 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Treatment should be delayed 1-2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consider discontinuing irinotecan. See tables.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Colorectal Cancer: Single-Agent Schedule: Recommended Dosage Modifications",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col width=\"120\">",
"     </col>",
"     <col width=\"130\">",
"     </col>",
"     <col width=\"120\">",
"     </col>",
"     <col width=\"130\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Toxicity NCI Grade",
"         <sup>",
"          2",
"         </sup>",
"         (Value)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         During a Cycle of Therapy",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         At Start of Subsequent Cycles of Therapy (After Adequate Recovery), Compared to Starting Dose in Previous Cycle",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weekly",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weekly",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Once Every 3 Weeks",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         All dose modifications should be based on the worst preceding toxicity.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         National Cancer Institute Common Toxicity Criteria (version 1.0).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Excludes alopecia, anorexia, asthenia.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No toxicity",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &uarr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"         up to a maximum dose of 150 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Neutropenia",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 (1500-1999/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 (1000-1499/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 (500-999/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 (&lt;500/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Neutropenic Fever",
"         </b>",
"         (grade 4 neutropenia and &ge; grade 2 fever)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved, then &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Other Hematologic Toxicities",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Dose modifications for leukopenia, thrombocytopenia, and anemia during a course of therapy and at the start of subsequent courses of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Diarrhea",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 (2-3 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 (4-6 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 (7-9 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 (&ge;10 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Other Nonhematologic Toxicities",
"          <sup>",
"           3",
"          </sup>",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 25 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 50 mg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Colorectal Cancer: Combination Schedules: Recommended Dosage Modifications",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col width=\"120\">",
"     </col>",
"     <col width=\"190\">",
"     </col>",
"     <col width=\"190\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Toxicity NCI",
"         <sup>",
"          2",
"         </sup>",
"         Grade (Value)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         During a Cycle of Therapy",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         At the Start of Subsequent Cycles of Therapy (After Adequate Recovery), Compared to the Starting Dose in the Previous Cycle",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         All dose modifications should be based on the worst preceding toxicity.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         National Cancer Institute Common Toxicity Criteria (version 1.0).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Excludes alopecia, anorexia, asthenia.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No toxicity",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Neutropenia",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 (1500-1999/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 (1000-1499/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 1 dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 (500-999/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 1 dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 1 dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 (&lt;500/mm",
"         <sup>",
"          3",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 2 dose levels",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 2 dose levels",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Neutropenic Fever",
"         </b>",
"         (grade 4 neutropenia and &ge; grade 2 fever)",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved, then &darr; 2 dose levels",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Other Hematologic Toxicities",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Dose modifications for leukopenia or thrombocytopenia during a course of therapy and at the start of subsequent courses of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Diarrhea",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 (2-3 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Delay dose until resolved to baseline, then give same dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2 (4-6 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to baseline, then &darr; 1 dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3 (7-9 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to baseline, then &darr; by 1 dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 1 dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 (&ge;10 stools/day &gt; pretreatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to baseline, then &darr; 2 dose levels",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 2 dose levels",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Other Nonhematologic Toxicities",
"          <sup>",
"           3",
"          </sup>",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 1, then &darr; 1 dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintain dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 1 dose level",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 1 dose level",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Omit dose until resolved to &le; grade 2, then &darr; 2 dose levels",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &darr; 2 dose levels",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Mucositis and/or stomatitis",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease only 5-FU, not irinotecan",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease only 5-FU, not irinotecan",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 20 mg/mL (2 mL, 5 mL, 25 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 20 mg/mL (2 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Camptosar&reg;: 20 mg/mL (2 mL, 5 mL, 15 mL) [contains sorbitol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F184435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer by I.V. infusion, usually over 90 minutes. Premedication with dexamethasone and a 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     blocker is recommended 30 minutes prior to administration; prochlorperazine may be considered for subsequent use (if needed). Consider atropine 0.25-1 mg I.V. or SubQ as premedication for or treatment of cholinergic symptoms (eg, increased salivation, rhinitis, miosis, diaphoresis, abdominal cramping) or early onset diarrhea.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The recommended regimen to manage late diarrhea is loperamide 4 mg orally at onset of late diarrhea, followed by 2 mg every 2 hours (or 4 mg every 4 hours at night) until 12 hours have passed without a bowel movement. If diarrhea recurs, then repeat administration. Loperamide should not be used for more than 48 consecutive hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F184500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Leucovorin calcium, oxaliplatin, palonosetron.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Gemcitabine, pemetrexed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic carcinoma of the colon or rectum",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F184489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cervical cancer (recurrent or metastatic), central nervous system tumors (recurrent glioblastoma), esophageal cancer, Ewing&rsquo;s sarcoma (recurrent or progressive), gastric cancer (metastatic or locally advanced), nonsmall cell lung cancer (advanced), ovarian cancer (recurrent), pancreatic cancer (advanced), small cell lung cancer (extensive stage)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Irinotecan may be confused with topotecan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency of adverse reactions reported for single-agent use of irinotecan only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Vasodilation (9% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Cholinergic toxicity (47% - includes rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing and intestinal hyperperistalsis); fever (44% to 45%), pain (23% to 24%), dizziness (15% to 21%), insomnia (19%), headache (17%), chills (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (46% to 72%), rash (13% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, late (83% to 88%; grade 3/4: 14% to 31%), diarrhea, early (43% to 51%; grade 3/4: 7% to 22%), nausea (70% to 86%), abdominal pain (57% to 68%), vomiting (62% to 67%), cramps (57%), anorexia (44% to 55%), constipation (30% to 32%), mucositis (30%), weight loss (30%), flatulence (12%), stomatitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (60% to 97%; grades 3/4: 5% to 7%), leukopenia (63% to 96%, grades 3/4: 14% to 28%), thrombocytopenia (96%, grades 3/4: 1% to 4%), neutropenia (30% to 96%; grades 3/4: 14% to 31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (84%), alkaline phosphatase increased (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (69% to 76%), back pain (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (22%), cough (17% to 20%), rhinitis (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (16%), infection (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (10%), hypotension (6%), thromboembolic events (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (9%), confusion (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal fullness (10%), dyspepsia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenic fever (grades 3/4: 2% to 6%), hemorrhage (grades 3/4: 1% to 5%), neutropenic infection (grades 3/4: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (10%), ascites and/or jaundice (grades 3/4: 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pneumonia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports: ALT increased, amylase increased, anaphylactoid reaction, anaphylaxis, angina, arterial thrombosis, bleeding, bradycardia, cardiac arrest, cerebral infarct, cerebrovascular accident, circulatory failure, colitis, dysrhythmia, embolus, gastrointestinal bleeding, gastrointestinal obstruction, hepatomegaly, hyperglycemia, hypersensitivity, hyponatremia, ileus, interstitial pulmonary disease (IPD), intestinal perforation, ischemic colitis, lipase increased, lymphocytopenia, megacolon, MI, myocardial ischemia, neutropenic typhlitis, pancreatitis, paresthesia, peripheral vascular disorder, pulmonary embolus; pulmonary toxicity (dyspnea, fever, reticulonodular infiltrates on chest x-ray); renal failure (acute), renal impairment, thrombocytopenia (immune mediated), thrombophlebitis, thrombosis, typhlitis, ulcerative colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In limited pediatric experience, dehydration (often associated with severe hypokalemia and hyponatremia) was among the most significant grade 3/4 adverse events, with a frequency up to 29%. In addition, grade 3/4 infection was reported in 24%.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to irinotecan or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: May cause severe myelosuppression.",
"     </b>",
"     Deaths due to sepsis following severe neutropenia have been reported. Complications due to neutropenia should be promptly managed with antibiotics. Therapy should be temporarily discontinued if neutropenic fever occurs or if the absolute neutrophil count is &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . The dose of irinotecan should be reduced if there is a clinically significant decrease in the total WBC (&lt;200/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), neutrophil count (&lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), hemoglobin (&lt;8 g/dL), or platelet count (&lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ). Routine administration of a colony-stimulating factor is generally not necessary, but may be considered for patients experiencing significant neutropenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colitis: Colitis, complicated by ulceration, bleeding, ileus, and infection has been reported. Initiate antibiotics promptly in patients with ileus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea:",
"     <b>",
"      [U.S. Boxed Warning]: Severe diarrhea may be dose-limiting and potentially fatal; early-onset and late-onset diarrhea may occur.",
"     </b>",
"     Early diarrhea occurs during or within 24 hours of receiving irinotecan and is characterized by cholinergic symptoms (eg, increased salivation, rhinitis, miosis, diaphoresis, flushing, abdominal cramping, lacrimation); may be prevented or treated with atropine. Late diarrhea occurs more than 24 hours after treatment which may lead to dehydration, electrolyte imbalance, or sepsis; may be life-threatening and should be promptly treated with loperamide. Dose reductions may be recommended for future doses within the current cycle. Antibiotics may be necessary if patient develops ileus, fever, or severe neutropenia. Patients with diarrhea should be carefully monitored and treated promptly; may require fluid and electrolyte therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions (including anaphylaxis) have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Fatal cases of interstitial pulmonary disease (IPD)-like events have been reported with single-agent and combination therapy. Promptly evaluate changes in baseline pulmonary symptoms or any new-onset pulmonary symptoms. Discontinue all chemotherapy if IPD is diagnosed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: Renal impairment and acute renal failure have been reported, possibly due to dehydration secondary to diarrhea. Use with caution in patients with renal impairment; not recommended in patients on dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: Thromboembolic events have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bowel obstruction: Patients with bowel obstruction should not be treated with irinotecan until resolution of obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; exposure to the active metabolite (SN-38) is increased; toxicities may be increased. Patients with even modest elevations in total serum bilirubin levels (1-2 mg/dL) have a significantly greater likelihood of experiencing first-course grade 3 or 4 neutropenia than those with bilirubin levels that were &lt;1 mg/dL. Patients with abnormal glucuronidation of bilirubin, such as those with Gilbert's syndrome, may also be at greater risk of myelosuppression when receiving therapy with irinotecan. Use caution when treating patients with known hepatic dysfunction or hyperbilirubinemia; dosage adjustments should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP-mediated drug interactions:  High potential for CYP-mediated drug interactions. Enzyme inducers may decrease exposure to irinotecan and SN-38 (active metabolite); enzyme inhibitors may increase exposure. For use in patients with CNS tumors (unlabeled use), selection of antiseizure medications which are not enzyme inducers is preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunization: Avoid vaccination with live vaccines during treatment (risk of infection may be increased due to immunosuppression). Although the response to vaccines may be diminished, inactivated vaccines may be administered during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients with comorbid conditions, or baseline performance status of 2; close monitoring and dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients homozygous/heterozygous for the UGT1A1*28 allele: Patients homozygous for the UGT1A1*28 allele are at increased risk of neutropenia; initial one-level dose reduction should be considered for both single-agent and combination regimens. Heterozygous carriers of the UGT1A1*28 allele may also be at increased risk; however, most patients have tolerated normal starting doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pelvic/abdominal radiation recipients: Use with caution in patients who have previously received pelvic/abdominal radiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorbitol: Product contains sorbitol; do not use in patients with hereditary fructose intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Except as part of a clinical trial, use in combination with the fluorouracil and leucovorin &ldquo;Mayo Clinic&rdquo; regimen is not recommended. Increased toxicity has also been noted in patients with a baseline performance status of 2 in other combination regimens containing irinotecan, leucovorin, and fluorouracil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: For I.V. use only; monitor infusion site; may cause local tissue necrosis or thrombophlebitis if extravasation occurs (the manufacturer recommends flushing the site with sterile water and ice application).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F184487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP3A4 (major), P-glycoprotein, SLCO1B1, UGT1A1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Irinotecan. The metabolism (via glucuronidation) of the active SN-38 metabolite may be primarily impacted by this interaction.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced. Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with carbamazepine, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Irinotecan. Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenytoin, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced. Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenobarbital, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced. Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with phenytoin, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: May increase serum concentrations of the active metabolite(s) of Irinotecan. Regorafenib may increase the serum concentration of Irinotecan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May increase the serum concentration of Irinotecan. Sorafenib may also increase the concentration of the active metabolite of irinotecan, SN-38.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Irinotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F184451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid St John's wort (decreases the efficacy of irinotecan).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. Women of childbearing potential should avoid becoming pregnant while receiving treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3197632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3342893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains sorbitol; do not use in patients with hereditary fructose intolerance.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Camptosar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/2 mL (2 mL): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (5 mL): $75.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/15 mL (15 mL): $225.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Irinotecan HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/2 mL (2 mL): $36.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (5 mL): $54.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/25 mL (25 mL): $158.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F184430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, and hemoglobin with each dose; bilirubin, electrolytes (with severe diarrhea); bowel movements and hydration status; monitor infusion site for signs of inflammation and avoid extravasation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A test is available for genotyping of UGT1A1; however, guidelines for use are not established and not recommended in patients who have experienced toxicity as a dose reduction is already recommended (NCCN Colon Cancer Guidelines v.1.2011)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Campto (AT, BE, BF, BG, BJ, CH, CI, CL, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IT, JP, KE, KP, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, PH, PK, PL, PT, RU, SC, SD, SE, SG, SK, SL, SN, TH, TN, TR, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Camptolem (TH);",
"     </li>",
"     <li>",
"      Camptosar (AR, AU, BO, BR, CN, CO, CR, DO, EC, GT, MX, NI, NZ, PA, PE, PR, SV, UY, VE);",
"     </li>",
"     <li>",
"      Camtecan (KP);",
"     </li>",
"     <li>",
"      Crabcan (KP);",
"     </li>",
"     <li>",
"      Efixano (PY);",
"     </li>",
"     <li>",
"      Herocan (TW);",
"     </li>",
"     <li>",
"      Indotecan (KP);",
"     </li>",
"     <li>",
"      Innocan (TW);",
"     </li>",
"     <li>",
"      Irenax (TW);",
"     </li>",
"     <li>",
"      Irican (PH);",
"     </li>",
"     <li>",
"      Irino (TH);",
"     </li>",
"     <li>",
"      Irinocyt (CO);",
"     </li>",
"     <li>",
"      Irinogen (EC);",
"     </li>",
"     <li>",
"      Irinoll (TH);",
"     </li>",
"     <li>",
"      Irinotel (IN, TH, TW);",
"     </li>",
"     <li>",
"      Irinotesin (HK, PH, SG, TH);",
"     </li>",
"     <li>",
"      Iritecan (KP);",
"     </li>",
"     <li>",
"      Irnocam (MY);",
"     </li>",
"     <li>",
"      Linatecan (PE);",
"     </li>",
"     <li>",
"      Lritecin (KP);",
"     </li>",
"     <li>",
"      Pipetecan (AR);",
"     </li>",
"     <li>",
"      Terican (MX);",
"     </li>",
"     <li>",
"      Topotecin (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Irinotecan and its active metabolite (SN-38) bind reversibly to topoisomerase I-DNA complex preventing religation of the cleaved DNA strand. This results in the accumulation of cleavable complexes and double-strand DNA breaks. As mammalian cells cannot efficiently repair these breaks, cell death consistent with S-phase cell cycle specificity occurs, leading to termination of cellular replication.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 33-150 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: Predominantly albumin; Irinotecan: 30% to 68%, SN-38 (active metabolite): ~95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic to SN-38 (active metabolite) by carboxylesterase enzymes; SN-38 undergoes conjugation by UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. Conversion of irinotecan to SN-38 is decreased and glucuronidation of SN-38 is increased patients who smoke cigarettes, resulting in lower levels of the metabolite and overall decreased systemic exposure. SN-38 is increased by UGT1A1*28 polymorphism (10% of North Americans are homozygous for UGT1A1*28 allele). The lactones of both irinotecan and SN-38 undergo hydrolysis to inactive hydroxy acid forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Irinotecan: 6-12 hours; SN-38: ~10-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: SN-38: Following 90-minute infusion: &sim;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine: Irinotecan (11% to 20%), metabolites (SN-38 &lt;1%, SN-38 glucuronide, 3%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ajani JA, Baker J, Pisters PW, et al, &ldquo;CPT-11 Plus Cisplatin in Patients With Advanced, Untreated Gastric or Gastroesophageal Junction Carcinoma: Results of a Phase II Study,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 94(3):641-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/11857295/pubmed\" id=\"11857295\" target=\"_blank\">",
"        11857295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bouch&eacute; O, Raoul JL, Bonnetain F, et al, &ldquo;Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(21):4319-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/15514373/pubmed\" id=\"15514373\" target=\"_blank\">",
"        15514373",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casey DA, Wexler LH, Merchant MS, et al, &ldquo;Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(6):1029-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/19637327/pubmed\" id=\"19637327\" target=\"_blank\">",
"        19637327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chen G, Huynh M, Fehrenbacher L, et al, &ldquo;Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1401-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/19204194/pubmed\" id=\"19204194\" target=\"_blank\">",
"        19204194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conroy Y, Desseigne F, Ychou M, et al, &ldquo;Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) Versus Gemcitabine (G) as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma (MPA): Preplanned Interim Analysis Results of the PRODIGE 4/ACCORD 11 Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(15s):4010 [abstract #4010 from the 2010 American Society of Clinical Oncology Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conroy T, Paillot B, Fran&ccedil;ois E, et al, &ldquo;Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer--A Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(6):1228-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/15718320/pubmed\" id=\"15718320\" target=\"_blank\">",
"        15718320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dank M, Zaluski J, Barone C, et al, &ldquo;Randomized Phase III Study Comparing Irinotecan Combined With 5-Fluorouracil and Folinic Acid to Cisplatin Combined With 5-Fluorouracil in Chemotherapy Naive Patients With Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(8):1450-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/18558665/pubmed\" id=\"18558665\" target=\"_blank\">",
"        18558665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falcone A, Ricci S, Brunetti I, et al, &ldquo;Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(13):1670-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/17470860/pubmed\" id=\"17470860\" target=\"_blank\">",
"        17470860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman HS, Prados MD, Wen PY, et al, &ldquo;Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(28):4733-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/19720927/pubmed\" id=\"19720927\" target=\"_blank\">",
"        19720927",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanna N, Bunn PA Jr, Langer C, et al, &ldquo;Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(13):2038-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/16648503/pubmed\" id=\"16648503\" target=\"_blank\">",
"        16648503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hermes A, Bergman B, Bremnes R, et al, &ldquo;Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(26):4261-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/18779613/pubmed\" id=\"18779613\" target=\"_blank\">",
"        18779613",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirose T, Horichi, N, Ohmori T, et al, &ldquo;Phase II Study of Irinotecan and Carboplatin in Patients With the Refractory or Relapsed Small Cell Lung Cancer,&rdquo;",
"      <i>",
"       Lung Cancer",
"      </i>",
"      , 2003, 40(3):333-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/12781433/pubmed\" id=\"12781433\" target=\"_blank\">",
"        12781433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ilson DH, Saltz L, Enzinger P, et al, &ldquo;Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(10):3270-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/10506629/pubmed\" id=\"10506629\" target=\"_blank\">",
"        10506629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leary A, Assersohn L, Cunningham D, et al, &ldquo;A Phase II Trial Evaluating Capecitabine and Irinotecan as Second Line Treatment in Patients With Oesophago-Gastric Cancer Who Have Progressed On, or Within 3 Months of Platinum-Based Chemotherapy,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2009, 64(3):455-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/19104814/pubmed\" id=\"19104814\" target=\"_blank\">",
"        19104814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marsh S and McLeod HL, &ldquo;Pharmacogenetics of Irinotecan Toxicity,&rdquo;",
"      <i>",
"       Pharmacogenomics",
"      </i>",
"      , 2004, 5(7):835-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/15469406/pubmed\" id=\"15469406\" target=\"_blank\">",
"        15469406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathijssen RH, van Alphen RJ, Verweij J, et al, &ldquo;Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11),&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2001, 7(8):2182-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/11489791/pubmed\" id=\"11489791\" target=\"_blank\">",
"        11489791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moehler M, Kanzler S, Geissler M, et al, &ldquo;A Randomized Multicenter Phase II Study Comparing Capecitabine With Irinotecan or Cisplatin in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010 21(1):71-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/19605504/pubmed\" id=\"19605504\" target=\"_blank\">",
"        19605504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Colon Cancer,&rdquo; Version 1.2013. Available at file://www.nccn.org/professionals/physician_gls/PDF/colon.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Ovarian Cancer,&rdquo; Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noda K, Nishiwaki Y, Kawahara M, et al, &ldquo;Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(2):85-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/11784874/pubmed\" id=\"11784874\" target=\"_blank\">",
"        11784874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohe Y, Ohashi Y, Kubota K, et al, &ldquo;Randomized Phase III Study of Cisplatin Plus Irinotecan Versus Carboplatin Plus Paclitaxel, Cisplatin Plus Gemcitabine, and Cisplatin Plus Vinorelbine for Advanced Non-Small-Cell Lung Cancer: Four-Arm Cooperative Study in Japan,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2007, 18(2):317-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/17079694/pubmed\" id=\"17079694\" target=\"_blank\">",
"        17079694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park SH, Choi EY, Bang SM, et al, &ldquo;Salvage Chemotherapy With Irinotecan and Cisplatin in Patients With Metastatic Gastric Cancer Failing Both 5-Fluorouracil and Taxanes,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2005, 16(6):621-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/15930889/pubmed\" id=\"15930889\" target=\"_blank\">",
"        15930889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pillot GA, Read WL, Hennenfent KL, et al, &ldquo;A Phase II Study of Irinotecan and Carboplatin in Advanced Non-Small Cell Lung Cancer With Pharmacogenomic Analysis: Final Report,&rdquo;",
"      <i>",
"       J Thorac Oncol",
"      </i>",
"      , 2006, 1(9):972-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/17409981/pubmed\" id=\"17409981\" target=\"_blank\">",
"        17409981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raymond E, Boige V, Faivre S, et al, &ldquo;Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(21):4303-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/12409328/pubmed\" id=\"12409328\" target=\"_blank\">",
"        12409328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rothenberg ML, Eckardt JR, Kuhn JG, et al, \"Phase II Trial of Irinotecan in Patients With Progressive or Rapidly Recurrent Colorectal Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(4):1128-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/8648367/pubmed\" id=\"8648367\" target=\"_blank\">",
"        8648367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmittel A, Fischer von Weikersthal L, Sebastian M, et al, &ldquo;A Randomized Phase II Trial of Irinotecan Plus Carboplatin Versus Etoposide Plus Carboplatin Treatment in Patients With Extended Disease Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2006, 17(4):663-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/16423848/pubmed\" id=\"16423848\" target=\"_blank\">",
"        16423848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toffoli G, Cecchin E, Corona G, et al, &ldquo;The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(19):3061-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/16809730/pubmed\" id=\"16809730\" target=\"_blank\">",
"        16809730",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker SE, Law S, and Puodziunas A, &ldquo;Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers,&rdquo;",
"      <i>",
"       Can J Hosp Pharm",
"      </i>",
"      , 2005, 58(4): 212-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Bol JM, Loos WJ, de Jong FA, et al, &ldquo;Effect of Omeprazole on the Pharmacokinetics and Toxicities of Irinotecan in Cancer Patients: A Prospective Cross-Over Drug-Drug Interaction Study,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2011, 47(6):831-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/21216137/pubmed\" id=\"21216137\" target=\"_blank\">",
"        21216137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van der Bol JM, Mathijssen RH, Loos WJ, et al, &ldquo;Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(19):2719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/17563393/pubmed\" id=\"17563393\" target=\"_blank\">",
"        17563393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verschraegen CF, Levy T, Kudelka AP, et al, &ldquo;Phase II Study of Irinotecan in Prior Chemotherapy-Treated Squamous Cell Carcinoma of the Cervix,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 5(2):625-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/9053486/pubmed\" id=\"9053486\" target=\"_blank\">",
"        9053486",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al, &ldquo;Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(30):4722-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/41/7834/abstract-text/17947719/pubmed\" id=\"17947719\" target=\"_blank\">",
"        17947719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8573 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7834=[""].join("\n");
var outline_f7_41_7834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708954\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184455\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184456\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184493\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184460\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10819706\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184461\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5519575\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184462\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184494\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184432\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184417\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184435\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184500\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184433\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184489\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401643\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184491\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184438\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184421\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184487\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184426\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184451\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184428\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184440\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184468\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3197632\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3342893\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323228\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184430\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184441\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184420\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184437\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8573\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8573|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/44/1733?source=related_link\">",
"      Irinotecan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/48/15113?source=related_link\">",
"      Irinotecan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_41_7835="Physiologic causes of constipation in infants and children";
var content_f7_41_7835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic causes of constipation in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Type of formula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cow's milk intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low dietary fiber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inadequate&nbsp;fluid intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hot weather",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia nervosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Starvation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Tunnessen WJ. Constipation and fecal retention. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7835=[""].join("\n");
var outline_f7_41_7835=null;
var title_f7_41_7836="Toilet training guidance";
var content_f7_41_7836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticipatory guidance for toilet training",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Visit",
"       </td>",
"       <td class=\"subtitle1\">",
"        Action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        12-month",
"       </td>",
"       <td>",
"        Discourage active toilet training until after 18-month visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate parental expectations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-month",
"       </td>",
"       <td>",
"        Discuss the criteria for readiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        18-month",
"       </td>",
"       <td>",
"        Review the criteria for readiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide written information on the toilet-training process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        24-month",
"       </td>",
"       <td>",
"        Evaluate the child's readiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide feedback on progress and plan if training has begun",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss nighttime enuresis if the child has daytime control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congratulate the child and parents if the child is toileting independently",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        36-month",
"       </td>",
"       <td>",
"        Provide feedback on progress and plan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss toileting refusal issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss nighttime enuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss reasons for follow-up before 48-month visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congratulate the child and parents if the child is toileting independently",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        48-month",
"       </td>",
"       <td>",
"        Discuss nighttime enuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Revisit any medical causes that may be interfering with completion of toilet training (eg, constipation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refer to behavior specialist if child refuses daytime training",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Michel RS. Pediatrics in Review 1999; 20:240.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7836=[""].join("\n");
var outline_f7_41_7836=null;
var title_f7_41_7837="Histolog classification STS I";
var content_f7_41_7837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic classification of soft tissue sarcomas - I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of adipose tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiolipoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lipoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hibernoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myolipoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angiomyolipoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate (locally aggressive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atypical lipoma/well-differentiated liposarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dedifferentiated liposarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myxoid liposarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleomorphic liposarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Round cell liposarcoma, Mixed-type liposarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        So-called fibrohistiocytic tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giant cell tumor of the tendon sheath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diffuse-type giant cell tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deep benign fibrous histiocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intermediate (rarely metastasizing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plexiform fibrohistiocytic tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giant cell tumor of soft tissues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleomorphic malignant fibrous histiocytoma (MFH)/undifferentiated pleomorphic sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Giant cell MFH/undifferentiated pleomorphic sarcoma with giant cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory MFH/undifferentiated pleomorphic sarcoma with prominent inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of skeletal muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhabdomyoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhabdomyosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tumors of smooth muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deep leiomyoma, Genital leiomyoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angioleiomyoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leiomyosarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Perivascular tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glomus tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Malignant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant glomus tumor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Fletcher CDM, Unni KK, Mertens F, Eds. Pathology and Genetics of tumours of soft tissue and bone. Lyon, IARC 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7837=[""].join("\n");
var outline_f7_41_7837=null;
var title_f7_41_7838="Drugs removed with HP";
var content_f7_41_7838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs and chemicals removed with hemoperfusion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Barbiturates",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amobarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Butabarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hexabarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pentobarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenobarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Quinalbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Secobarbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thiopental",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vinalbital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Antidepressants",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Amitryptiline)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Imipramine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Tricyclics)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Metals",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aluminum*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cisplatin*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Iron*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thallium",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Miscellaneous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aminophylline",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cimetidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Fluoroacetamide)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Phencyclidine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenols",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Podophyllin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Theophylline",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Solvents, gases",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbon tetrachloride",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ethylene oxide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Trichloroethane",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Antimicrobials/anticancer",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Adriamycin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ampicillin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carmustine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chloramphenicol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chloroquine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Clindamycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dapsone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Doxorubicin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gentamicin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Isoniazid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Methotrexate)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Thiabendazole",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vancomycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pentamidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Analgesics, antirheumatic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acetaminophen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acetylsalicylic acid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Colchicine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          D-propoxyphyene",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methylsalicylate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phenylbutazone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Salicylic acid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tramadol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cardiovascular",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Digoxin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diltazem",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Disopyramide)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Metoprolol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          N-acetylprocainamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Procainamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Quinidine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cibenzoline",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Plant and animal toxins, herbicides, insecticides",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amanitin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlordane",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Demeton sulfoxide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dimethoate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diquat",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methylparathion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Nitrostigmine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Organophosphates&bull;",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phalloidin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Polychlorinated biphenyls",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Paraquat",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Parathion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Star fruit",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tetramine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Nonbarbiturate hypnotics, sedatives and tranquilizers",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbromal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chloral hydrate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlorpromazine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          (Diazepam)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diphenhydramine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ethchlorvynol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Glutethimide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Meprobamate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methaqualone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methsuximide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methyprylon",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Promazine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Promethazine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Valproic acid",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ( ): not well removed.",
"     <br>",
"      * Removed with chelating agent.",
"      <br>",
"       &bull; With lipid emulsion.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7838=[""].join("\n");
var outline_f7_41_7838=null;
var title_f7_41_7839="Epigastric hernia";
var content_f7_41_7839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epigastric hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An epigastric hernia occurs when bowel protrudes through a weakness in the linea alba. The small bulge appears midline between the xiphoid process and the umbilicus. It may be discovered only on palpation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weber, J, Kelley, J. Health Assessment in Nursing, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_41_7839=[""].join("\n");
var outline_f7_41_7839=null;
